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PROFIL IMUNOFENOTIPIK MONOSITIK MIKROPARTIKAL YANG 
DIREMBES DARIPADA SEL DARAH MONOSIT MANUSIA DAN 





Monositik mikropartikal (mMP) adalah mikrovesikal heterogen kecil yang 
dirembes oleh sel monosit yang terhasil daripada proses pengaktifan atau apoptosis. 
Peningkatan paras edaran mMP yang ketara dalam pelbagai jenis penyakit 
menunjukkan potensinya sebagai biopenanda. Walau bagaimanapun, peranan 
fenotipik dan fungsi mMP yang terhasil daripada sel darah monosit manusia tidak 
diketahui. Kajian ini bertujuan untuk mengenal pasti ciri-ciri mMP yang dirembes 
daripada sel monosit, CD14+ monosit, dan CD16+ monosit melalui penilaian terhadap 
pengekspresan antigen permukaan dan mengenal pasti peranannya dalam 
penggumpalan dan fungsi sel endotelia. Kesemua subjenis sel monosit telah dikultur 
dengan kehadiran lipopolisakarida (LPS) selama 18 jam. Monositik MP seterusnya 
diasingkan daripada supernatan yang telah dikultur melalui kaedah ultrapengemparan 
sebelum dianalisa menggunakan teknik sitometri aliran. Sementara itu, penilaian masa 
protrombin (PT) telah dijalankan untuk menilai potensi mMP dalam penggumpalan. 
Untuk mengkaji peranan mMP terhadap fungsi sel endotelial, mMP telah dikultur 
bersama dengan sel endotelial vena umbilikus manusia (HUVEC). Kadar ekspresi 
intercellular adhesion molecule 1’ (ICAM-1) dan ‘vascular cell adhesion molecule 1’ 
(VCAM-1) pada sel endotelia serta perembesan mikropartikal endotelial (eMP) 




kaedah ‘real-time PCR’ dan teknik sitometri aliran. Kajian ini telah menunjukkan 
bahawa CD14 dan CD16 telah diekspres pada permukaan mMP daripada kesemua 
subjenis sel monosit pada corak yang sama seperti sel induk mereka. Tambahan pula, 
mMP mengekspres CD142 dan masa penggumpalan yang lebih singkat dengan 
kehadiran mMP yang terhasil daripada sel monosit yang dirangsang dengan LPS. 
Sementara itu, tahap pengekspresan ‘intercellular adhesion molecule 1’ (ICAM-1), 
‘vascular cell adhesion molecule 1’ (VCAM-1) dan kadar mikropartikal endotelial 
(eMP) telah meningkat dengan kehadiran mMP daripada sel monosit. Hasil kajian ini 
mencadangkan bahawa kombinasi ‘Annexin-V’ dengan CD14 dan CD16 adalah 
penanda permukaan sel yang berpotensi untuk pengesanan mMP. Tambahan pula, 
mMP berpotensi untuk memiliki ciri pro-penggumpalan yang mana CD142 pada 
permukaannya berkemungkinan memainkan peranan utama dalam penggumpalan dan 
mMP mampu untuk mengaktifkan sel endotelial sekaligus mencadangkan potensi 


















IMMUNOPHENOTYPIC PROFILES OF MONOCYTIC 
MICROPARTICLES DERIVED FROM HUMAN BLOOD MONOCYTES 
AND THEIR POTENTIAL ROLE IN COAGULATION AND 




Monocytic microparticles (mMP) are small heterogeneous microvesicles 
derived from monocytes following cellular activation or apoptosis. Significant 
elevation of circulating mMP in various diseases increases its potential as a biomarker. 
However, the phenotypic and functional role of mMP derived from human blood 
monocytes is unknown. This study intended to characterise mMP derived from whole 
monocytes, CD14+ monocytes, and CD16+ monocytes by assessing surface antigen 
expressions and identify their role in coagulation and endothelial cell function. All 
monocyte subtypes were cultured in the presence of lipopolysaccharides (LPS) for 18 
hours. Monocytic MP were purified from culture supernatants by ultracentrifugation 
before being analysed using flow cytometry. Meanwhile, prothrombin time (PT) assay 
was performed to assess the coagulation potential of mMP. To assess the role mMP in 
endothelial cells function, mMP were co-cultured with human umbilical vein 
endothelial cells (HUVEC). The expression level of ICAM-1 and VCAM-1 on 
HUVEC as well as the release of endothelial MP (eMP) upon mMP-HUVEC co-
culture were then determined by using real time PCR and flow cytometry respectively. 
This study has shown that CD14 and CD16 were expressed on all monocyte subtypes-
derived mMP similar to their origin cells. Additionally, CD142 were expressed on 




monocyte-derived mMP. Meanwhile, the expression of intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) were 
increased in the presence of mMP derived from whole monocytes and mMP increased 
the level of endothelial microparticles (eMP). These findings suggest that Annexin-V 
in combination with CD14 and CD16 could be possible surface markers for mMP 
phenotyping. Furthermore, mMP may possess procoagulant properties as CD142 on 
their surface may be the major player in coagulation and they were able to activate 








Microparticles (MP) are a population of submicron vesicles released from various cell 
types following activation or apoptosis. As MP are derived from different cell types, 
different MP exhibit different identities and play different roles (Rousseau et al., 
2015). Microparticles carry their original cell’s characteristics including membrane 
proteins, cytosolic contents and genetic information (Diehl et al., 2012). During MP 
formation, the cytoskeleton membrane of activated cells undergoes phospholipids 
rearrangement which results in the expression of phosphatidylserine (PS) on the outer 
membrane layer. The detection of MP is performed by the identification of origin cell 
antigens in combination with PS, which is directly targeted by Annexin-V (Voudoukis 
et al., 2016). For example, monocyte-derived MP can be detected by using anti-CD14 
(Bardelli et al., 2012), platelet-derived MP can be identified using anti-CD41 
(Flaumenhaft et al., 2009), and anti-CD31 is used for identifying endothelial cell-
derived MP (Shantsila, 2008). 
 
Microparticles participate in physiological and pathological processes at the molecular 
level (Lu et al., 2017). They serve as important mediators in intercellular interaction 
particularly in the signalling pathway in an autocrine or paracrine manner (Benameur 
et al., 2019). Under normal conditions, MP act as cell signalling molecules by 
expressing protein ligands and transferring mRNA between cells (Ratajczak et al., 




their functions in terms of surface proteins and gene expression as well as cytosolic 
molecule activities (Barteneva et al., 2013). For instance, MP are capable of activating 
monocytes and endothelial cells via interleukin 1β (IL-1β) activity (Wang et al., 2011) 
as well as inducing proliferation and angiogenic activity in endothelial cells by the 
transfer of mRNA (Barteneva et al., 2013). Microparticles are also able to induce 
expression of tissue factor (TF) and cytokine secretion by endothelial cells (Wen et 
al., 2014). Elevated level of MP has been observed in various disease states suggesting 
their crucial role as biomarkers. Previous studies have reported the association of 
increased MP number with cardiovascular disease (Batool, 2013), autoimmune disease 
(Halim et al., 2016), and cancer (Wu et al., 2013).  
 
Monocytes are one of the sources of circulating MP in peripheral blood. During 
inflammation, monocytes participate in innate immunity as phagocytic cells to destroy 
invading pathogens. Monocytes consist of three subsets, which are distinguished based 
on the expression of CD14 and CD16. The three monocyte subsets are the classical 
CD14++CD16− monocytes, non-classical CD14+CD16++ monocytes, and intermediate 
CD14++CD16+ monocytes (Stansfield and Ingram, 2015; Ziegler-Heitbrock et al., 
2010). The different distribution of membrane CD14 and CD16 expression remarks 
their different functional properties in immune functions, phagocytic activity, and 
cytokine profiles. Activated monocytes subsets may release MP known as monocytic 
MP (mMP) in response to stimuli.  
 
Although circulating MP are mainly derived from platelets during normal condition, 
the release of mMP at high level has been observed during endotoxemia and 




TF on mMP membrane are thought to define their potential role in haemostasis 
(Aleman et al., 2011). A previous report has demonstrated that mMP may promote 
downstream thrombotic events by inducing the expression of TF and von Willebrand 
factors on endothelial cells (Essayagh et al., 2007). Apart from that, mMP have been 
shown to amplify inflammation by IL-1β activity as well as inducing intercellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) 
expressions by endothelial cells (Wang et al., 2011). However, the exact role of mMP 
in coagulation and inflammation particularly their interaction with endothelial cells 
remains unclear. Most mMP studies have been carried out using monocytic cell lines 
or primary monocytes without distinguishing their subsets. Therefore, this study 
intended to characterise the phenotypic properties of mMP derived from human 




1.2 Human peripheral blood mononuclear cells (PBMC) 
1.2.1 The origin and components of PBMC 
Human peripheral blood mononuclear cells (PBMC) are a population of peripheral 
immune cells that consist of a single round nucleus. In humans, the components of 
PBMC include lymphocytes, monocytes, natural killer cells, and dendritic cells. The 
composition of each cell type varies across individuals, with T cells are between 70% 
to 85%, B cells and natural killer cells are between 5% to 10% and 5% to 20% 
respectively as well as monocytes between 2% to 10% present as main constituents, 




2015). These circulating immune players are crucial in controlling immune activity in 
healthy individuals and are capable of responding to any intruders or pathogens in an 
inflammatory manner (Haudek-Prinz et al., 2012).  
 
 
1.2.2 PBMC isolation  
Peripheral blood and umbilical cord blood are the primary sources of PBMC.  Usually, 
whole blood is collected through venepuncture which is easy and less invasive, 
allowing for repeated sampling (Arosio et al., 2014). Isolation of PBMC from whole 
blood is commonly facilitated by density gradient centrifugation method using Ficoll-
Hypaque solution (Chan et al., 2013). A gradient medium permits the separation of 
blood cells in whole blood in which they are distributed in different layers based on 
their size and density.  
 
Ficoll-Hypaque solution contains sodium diatrizoate and Ficoll, a sucrose polymer 
with a high molecular weight allowing rouleaux formation of erythrocytes (Fuss et al., 
2009). With a specific gravity of 1.077 at room temperature, Ficoll-Hypaque solution 
successfully separates PBMC from granulocytes and erythrocytes as they are denser 
than lymphocytes, monocytes, and platelets, but less dense than granulocytes and 
erythrocytes (Kleiveland, 2015). Hence, mononuclear cells are collected on the top of 
the Ficoll-Hypaque layer, while erythrocytes and granulocytes are isolated at the 






Figure 1.1: Isolation of PBMC from whole blood. Ficoll-Hypaque solution is 
layered at the bottom of the whole blood followed by centrifugation at 544 × g for 20 
minutes. After centrifugation, blood components are separated in different layers 



















1.3 Human blood monocytes 
Monocytes are agranular leucocytes of myeloid lineage which circulate in the blood 
and act as the main mononuclear phagocytes. In healthy humans, monocytes account 
for approximately 2% to 10% of circulating leucocytes (Appleby et al., 2013; Yona 
and Jung, 2010), which is approximately 450 monocytes/L blood (Robbins and 
Swirski, 2010). The number of monocytes can rapidly elevate due to stress and disease 
conditions (Ziegler-Heitbrock, 2015). An increase in monocyte count or monocytosis 
suggests the presence of an infection or inflammation (Yang et al., 2014). 
 
 
1.3.1 The biology of monocytes 
Monocytes originate from haematopoietic stem cells (HSC) in the bone marrow 
through several progenitor stages (Figure 1.2). The HSC subsequently differentiate 
into multipotent progenitors (MPP) before producing two further progenitor cells 
which are CD34+ common myeloid progenitor cells (CMP) (Akashi et al., 2000) and 
common lymphoid progenitor cells (CLP) (Tortora and Derrickson, 2011). The CMP 
develop into erythrocytes, platelets, and leucocytes, while CLP develop into 
lymphocytes. Some of the CMP then differentiate into either megakaryocytes–
erythrocytes progenitor cells (MEP) or granulocytes–macrophages progenitor cells 
(GMP) (Iwasaki and Akashi, 2007), which are important for erythroid-lineage cells 
and myeloid-lineage cells respectively. Subsequently, GMP further differentiate into 







Figure 1.2: Formation of human blood cells. Blood cells originate from 
haematopoietic stem cell (HSC) in the bone marrow through several committed 
progenitor stages including multipotent progenitor (MPP), common myeloid 
progenitors (CMP), and common lymphoid progenitors (CMP). Granulocytes–
macrophages progenitors (GMP) and megakaryocytes–erythrocytes progenitors 
(MEP) further differentiated from CMP. MEP develop into erythrocytes and 
megakaryocytes. GMP develop into granulocytes and monocytes. CMP further 
develop into natural killer cell, T lymphocytes, and B lymphocytes. (Modified 
















The development of blood cells from HSC involves cytokines and growth factors that 
actively regulate the development and proliferation of specific progenitor cells. 
Growth factors such as colony-stimulating factors (CSF) and interleukins (IL) trigger 
the differentiation of progenitor cells in the bone marrow (Tortora and Derrickson, 
2011). When the development process is complete, monocytes subsequently migrate 
to the circulation as inert cells. Monocytes migrate and mature at the site of infection 
following stimulation by pathogenic invaders such as bacteria and viruses. The 
lifespan of circulating monocytes in humans is one to three days before undergoing 
programmed-cell death (Yang et al., 2014). In fact, the short lifespan of monocytes 
explains that blood acts as an extensive myeloid progenitor’s reservoir, which allows 
for the continuous reformation of monocytes (Serbina and Pamer, 2006).  
 
 
1.3.2 General functions of monocytes 
Monocytes play an important role in both pro-inflammatory and anti-inflammatory 
immune responses. During inflammation, monocytes migrate to the site of 
inflammation and differentiate into M1 pro-inflammatory macrophages prior to the 
secretion of pro-inflammatory cytokines, including IL-6, IL-1β, and tumour necrosis 
factor α (TNF-α) (Murdock et al., 2015). On the other hand, anti-inflammatory 
monocytes differentiate into M2 anti-inflammatory macrophages, which are capable 
of producing anti-inflammatory cytokines, such as IL-10 and transforming growth 






The production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8 
by monocytes further results in oxidative and non-oxidative antimicrobial activities in 
an autocrine as well as paracrine manner, which lead to local and systemic 
inflammation. For example, TNF-α enhances the inflammatory response by 
monocytes in an autocrine manner through binding with TNF-α receptor 1 (TNFR1), 
which is expressed on monocytes, thus up regulating the release of pro-inflammatory 
cytokines (Gane et al., 2016). Meanwhile, the paracrine effect of IL-1β secreted by 
monocytes includes stimulating CD4+ T cell differentiation into T helper cell lineages 
(Santarlasci et al., 2013) as well as inducing the production of histamine by mast cells 
to promote vasodilation during inflammation (Arango Duque and Descoteaux, 2014). 
However, excessive monocyte activation and cytokine imbalance may result in 
exaggeration of inflammation (Peraçoli et al., 2003).  
 
Resolution of inflammation by monocytes is critical to decelerate inflammatory 
process and restore homeostasis. Monocytes synthesise and secrete anti-inflammatory 
cytokines such as IL-6, IL-10, and TGF-β1, which generate inhibitory effects to 
control the inflammation process. Endogenous IL-6 actively participates in 
neutralising toxic effects produced by elevated TNF-α secretion, therefore down 
regulating the activity of TNF-α (Peraçoli et al., 2003). Similarly, IL-10 secreted by 
monocytes supress various pro-inflammatory cytokines production and decrease 
scavenger function and antigen presentation activity by immune cells (Iyer and Cheng, 
2012). Meanwhile, monocytes may inhibit proliferation of T cells and exert 
immunosuppression effect on macrophage and leucocytes via TGF-β1 activity (Travis 





1.3.3 Blood monocyte heterogeneity  
Monocytes were originally thought as a single population in the blood circulation until 
the discovery of two different phenotypes in the late 1980s (Passlick et al., 1989). In 
2010, the nomenclature committee of the International Union of Immunological 
Societies (IUIS) classified monocytes into three functional subsets based on the 
expression of CD14 and CD16 antigens (Ziegler-Heitbrock et al., 2010). CD14 is 
identified as a co-receptor for lipopolysaccharides (LPS) and Toll-like receptor 4 (TLR 
4), while CD16 acts as Fcγ receptor III (FcγRIII) and engages in innate immune 
activity (Shantsila et al., 2011). The three monocyte subsets are the classical 
CD14++CD16− monocytes, non-classical CD14+CD16++ monocytes, and intermediate 
CD14++CD16+ monocytes. Previous studies have reported that different monocyte 
subsets have different biological functions, antigen-presenting activity, and phagocytic 
capacity (Table 1.1) (Gordon and Taylor, 2005; Wong et al., 2011; Zhao et al., 2009). 
However, when the non-classical CD14+CD16++ monocytes and intermediate 
CD14++CD16+ monocytes are unable to be separated in vitro, they are referred to as 












Table 1.1: Classification of human monocyte subsets. 
Monocyte subsets Surface receptor % in monocytes Functions 
Classical CD14++CD16− 85% to 90% Phagocytosis 
Non-classical CD14+CD16++ 7% to 8% Patrolling 
























1.3.3(a) Classical CD14++CD16− monocytes 
The classical CD14++CD16− monocytes are the major subset of monocytes, which 
exist approximately 85% to 90% in the circulation. The classical CD14++CD16− 
monocytes display high level of CD14 and lack CD16 expression on their surface 
(Stansfield and Ingram, 2015; Wong et al., 2011). The classical CD14++CD16− 
monocytes participate in the innate immune system by fighting against foreign 
organisms (Idzkowska et al., 2015). They exhibit premature phenotypes and migrate 
to sites of infection via extravasation before differentiating into macrophages (Patel et 
al., 2017; Reynolds and Haniffa, 2015). Monocyte extravasation is the movement of 
monocytes through the vascular endothelium to the infected site, which involves 
monocyte adhesion to the adhesion molecules ICAM-1 and VCAM-1, monocyte 
rolling, and monocyte transmigration through endothelial cells (Gerhardt and Ley, 
2015).  
 
The classical CD14++CD16− monocytes possess high phagocytic capacity as they 
express scavenger receptor type B class 1 (CD36 and CD163) (Mukherjee et al., 2015), 
receptor for complement component C1q1 (CD93), opsonin receptor FcγRI (CD64), 
and FcγRII (CD32) (Cros et al., 2010). These molecules are important for 
phagocytosis and destruction of pathogens by the classical CD14++CD16− monocytes. 
The classical CD14++CD16− monocytes also express CD11a/CD18 (Stec et al., 2012) 
and complement receptor 3 (CR3) (CD11b/CD18) (Wong et al., 2011), which are 
important in facilitating phagocytosis, intracellular signalling, intracellular adhesion, 
and monocyte migration (Lukácsi et al., 2017). This monocyte subset also presents 




(ROS), which are crucial in antimicrobial activity (Anbazhagan et al., 2014; Cros et 
al., 2010). This suggests that most of the classical CD14++CD16− monocytes are active 
scavenger cells in nature. 
 
Apart from that, the classical CD14++CD16− monocytes express high C-C chemokine 
receptor type 2 (CCR2), chemokine receptor type 1 (CXCR1), CXCR2, and CXCR4 
as well as adhesion molecule CD62L (L-selectin) (Ancuta et al., 2003). CCR2, a 
receptor for monocyte chemoattractant protein-1 (MCP-1/CCL) as well as CXCR1, 
CXCR2, CXCR4, and CD62L are important in assisting chemotaxis of monocytes in 
response to stimuli, particularly during inflammation (Kim et al., 2010). However, the 
expression of fractalkine receptor (CX3CR1) and CCR5 are low on the classical 
CD14++CD16− monocytes (Stec et al., 2012).  
 
Nevertheless, the classical CD14++CD16− monocytes are characterised by the 
capability to produce cytokines in response to stimulations such as LPS. The classical 
CD14++CD16− monocytes secrete various pro-inflammatory cytokines such as IL-10, 
IL-6, IL-8, IL-1β, and TNF-α (Cros et al., 2010), indicating their role in inflammation. 
The classical CD14++CD16− monocytes are lack of TLR 2, TLR 4, and TLR 5, as well 
as co-stimulatory molecules CD80, CD86, and major histocompatibility complex 
(MHC) class II molecules (Mukherjee et al., 2015). This suggests that the classical 
CD14++CD16− monocytes may have less role in antigen presentation. Antigen 
presentation is the process where peptides or antigens of foreign organisms are 




presentation is mediated by MHC class I and MHC class II molecules expressed on 




1.3.3(b) Non-classical CD14+CD16++ monocytes 
The non-classical CD14+CD16++ monocytes make up approximately 7% to 8% of total 
monocytes (Mukherjee et al., 2015). This monocyte subset expresses high CD16 and 
relatively low CD14. They are considered as the mature stage of monocytes compared 
to other subsets as they display similar characteristics with tissue macrophages in terms 
of low cytokine productions (Merino et al., 2011).  
 
The non-classical CD14+CD16++ monocytes are involved in inflammation and they 
are referred to as the pro-inflammatory subset due to their mobilisation during 
inflammation (Zawada et al., 2012). This monocyte subset exhibits high level of 
proteins RhoC, RhoF, and Rho GTPase; their activators guanine nucleotide exchange 
factors such as VAV2 and ARHGEF18; as well as downstream effector 
phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP5K2A), and protein 
kinase N1 (PKN1) (Wong et al., 2011). During cell movement, proteins RhoC, RhoF, 
and Rho GTPase coordinate actin cytoskeletal reorganisation and thus provide the 
driving force for cell chemotaxis (Wong et al., 2012). The presence of these proteins, 
which are particularly involved in cytoskeleton reorganisation represent the molecular 
basis of the non-classical CD14+CD16++ monocytes’ patrolling behaviour (Cros et al., 
2010). This patrolling property of the non-classical CD14+CD16++ monocytes is 




CD14+CD16++ monocytes patrol the resting endothelium layer for vasculature 
surveillance and subsequently detect infected cells and remove debris (Carlin et al., 
2013; Idzkowska et al., 2015). Additionally, the expression of chemokine receptor 
CX3CR1 is highly abundant on the non-classical CD14+CD16++ monocytes, although 
CCR2 and CD62L are not expressed on them (Carlin et al., 2013). Chemokine receptor 
CX3CR1 is important in mediating the accumulation of monocytes (Geissmann et al., 
2003), thus enhancing the patrolling capability of this monocyte subset.  
 
The non-classical CD14+CD16++ monocytes are less responsive to LPS 
(Skrzeczyńska‐Moncznik et al., 2008) but respond strongly to nucleic acids and 
viruses via TLR 7 and TLR 8 (Cros et al., 2010). Upon activation by nucleic acids and 
viruses, the non-classical CD14+CD16++ monocytes secrete high level of pro-
inflammatory cytokines such as IL-1β and TNF-α (Mukherjee et al., 2015) through the 
MyD88-MEK pathway (Cros et al., 2010), while LPS stimulation led to low level of 
IL-1β and TNF-α secretion (Wong et al., 2011). However, another study has shown 
that exposure of the non-classical CD14+CD16++ monocytes to LPS resulted in high 
production of IL-1β and TNF-α (Dutertre et al., 2012). This discrepancy may be due 
to the use of different anti-CD14 antibodies clone, since few anti-CD14 clones such as 
M5E2 has shown to inhibit LPS activity (Power et al., 2004). 
 
In contrast to the classical CD14++CD16− monocytes, the non-classical CD14+CD16++ 
monocytes express notably high level of co-stimulatory molecules CD80, CD86, and 
human leukocyte antigen DR (HLA-DR) as well as TLR 2, TLR 4, and TLR 5, 
indicating their role in antigen presentation (Mukherjee et al., 2015). The non-classical 




CD14++CD16− monocytes, the production of ROS, MPO, and lysozyme as well as the 
expression of scavenger receptor CD36 is low on the non-classical CD14+CD16++ 
monocytes (Idzkowska et al., 2015; Tallone et al., 2011). These properties are 
correlated to the low expression of CR3 and intermediate level of CR4 (CD11c/CD18) 
(Moniuszko et al., 2015), thus limiting their role in phagocytosis. 
 
 
1.3.3(c) Intermediate CD14++CD16+ monocytes 
The intermediate CD14++CD16+ monocytes are a minor population, constituting a 
small percentage with only 2% to 3% of total monocytes. This discrete subset 
expresses both CD14 and CD16 antigens on their surface (Ziegler-Heitbrock and 
Hofer, 2013). It has been reported that, monocyte maturation involves the transitional 
process of the classical monocytes to the intermediate monocytes before 
differentiating into mature non-classical monocytes (Idzkowska et al., 2015; Ziegler-
Heitbrock et al., 2010).  
 
The intermediate CD14++CD16+ monocytes have high phagocytic function and 
produce high level of ROS than other monocyte subsets (Rossol et al., 2012). 
Furthermore, the expression of both opsonin receptors FcγRIII and FcγRI as well as 
CD36 scavenger receptor are highly expressed on the intermediate CD14++CD16+ 
monocytes (Tallone et al., 2011), thus facilitating phagocytosis by this monocyte 
subset. The phagocytic capacity of the intermediate CD14++CD16+ monocytes is 
further enhanced with the high expression of CD11a/CD18, CR3 (Skrzeczyńska‐
Moncznik et al., 2008), and CR4 (Sulicka et al., 2013). These three types of β2 integrin 




to ICAM-1, ICAM-2, ICAM-3, and ICAM-5; CR3 integrin binds to complement 
proteins iC3b and C4b; and CR4 integrin binds to iC3b, ICAM-1, and fibrinogen 
(Podolnikova et al., 2015). The binding of these integrins with their main ligands 
subsequently mediates monocyte recruitment to the site of inflammation and 
phagocytosis via complement cascades (Schittenhelm et al., 2017).  
 
Additionally, the intermediate CD14++CD16+ monocytes play a role as antigen- 
presenting cells in enhancing immune response towards infections. The intermediate 
CD14++CD16+ monocytes display higher TLR 2, TLR 4, and TLR 5 compared to the 
other two monocyte subsets, as well as CD80 and CD86 co-stimulatory molecules, 
suggesting their significant role in pro-inflammatory function and antigen 
presentations (Mukherjee et al., 2015). Toll-like receptors 2, TLR 4 and TLR 5 are the 
co-receptors for CD14 expressed on monocytes, which are responsible in the 
recognition of bacterial lipoprotein, LPS, and bacterial flagellin respectively (Sabroe 
et al., 2003). Thus, they may elicit pro-inflammatory cytokine production, antigen 
presentation function, and secretion of multiple specific antibodies (Tadema et al., 
2011). The intermediate CD14++CD16+ monocytes have high expression of HLA-DR 
and enhance the proliferation of CD4+ T lymphocytes (Zawada et al., 2012). This 
further facilitates the activity of antigen presentation, which is important for initiating 
effector and memory T cell activation during infection.  
 
Some of the phenotypic and functional features of the intermediate CD14++CD16+ 
monocytes resemble both the classical CD14++CD16− and non-classical 
CD14+CD16++ monocytes, designating them as a translational population. The 




present on the classical CD14++CD16- monocytes, as well as CX3CR1, which is 
frequently expressed on the non-classical CD14+CD16++ monocytes (Idzkowska et al., 
2015). The interaction between CX3CR1 with its ligand CXL1 promotes leucocyte 
recruitment and migration via endothelial cells, thus suggesting their function in 
transendothelial migration and leucocyte infiltration, particularly during inflammation 
(Hettinger et al., 2013). In addition, this less abundant subset can be recognised by the 
expression of CCR5, which is a chemokine receptor of CCL5, macrophage 
inflammatory proteins 1α (MIP-1α), and MIP-1β as well as a viral co-receptor for 
human immunodeficiency virus (HIV) (Waller and Sampson, 2018). Additionally, the 
intermediate CD14++CD16+ monocytes has been reported to be involved in 
atherosclerotic lesions via MCP-1, by attracting MCP-1 to atherosclerotic lesions in a 
CCR5-dependent manner (Rogacev et al., 2011).  
 
The intermediate CD14++CD16+ monocytes are able to mobilise to the inflammatory 
site as well as to expand their number in numerous disease denotes their pro-
inflammatory functions (Mukherjee et al., 2015; Yang et al., 2014). The intermediate 
CD14++CD16+ monocytes release several inflammatory cytokines to the extracellular 
matrix such as IL-6, IL-8 (Cros et al., 2010), IL-1β, and TNF-α in a significantly higher 







1.4 Extracellular vesicles 
Extracellular vesicles (EV) are a heterogeneous population of vesicles with different 
sizes and contents which are released by cells under normal or disease conditions. They 
serve as important mediators of physiological process in normal and pathological 
states. Extracellular vesicles consist of exosomes and microparticles (MP), in which 
they can be distinguished mainly based on size, composition, and mechanism of 
formation (György et al., 2011) (Table 1.2). Exosomes are the smallest vesicles 
ranging between 30 and 100 nm in diameter. They consist of endocytic markers 
including tetraspanins and HSP73 (Chuo et al., 2018; Mathivanan et al., 2010) and 
have a low density approximately 1.13 to 1.19 g/mL (van der Pol et al., 2012). Upon 
fusion of multivesicular bodies containing intraluminal vesicles with the plasma 
membrane, exosomes are released from multivesicular bodies through exocytosis 
(Ståhl et al., 2019). Lipid compositions of exosome consist of cholesterol and 
phosphatidylserine (PS), and their cytosolic contents include proteins, mRNA, 
















Table 1.2: Characteristics of extracellular vesicles. 
 Exosomes Microparticles 





Plasma membrane  
Isolation 100,000 × g 20,000 × g 
Mechanism of 
formation 
Fusion of multivesicular 
bodies with the plasma 
membrane 
Outward blebbing of the 
plasma membrane 
Release 
Constitutive or cellular 
activation 




Enriched in cholesterol 
and ceramide, exposed 
phosphatidylserine, 
contain lipid raft 
Exposed 
phosphatidylserine, 
enriched in cholesterol 
and diacylglycerol, 









Integrins, selectins, parent 
cell antigens 








Meanwhile, MP are small heterogeneous vesicles ranging from 100 to 1000 nm which 
exhibit irregularity in terms of their shape due to different cellular origins (Morel et 
al., 2011b). Besides displaying several antigens of their origin cell and PS on their 
surface, MP contain cytosolic proteins, mRNA, miRNA, and lipids (Mause and Weber, 
2010). Microparticles are shed directly from cells by outward blebbing of the plasma 
membrane (Zaborowski et al., 2015). Although MP possess several characteristics that 
are similar to exosomes, MP can be separated from exosomes by centrifugation at 
20,000 × g (Mause and Weber, 2010).   
 
 
1.4.1 Microparticles  
Microparticles, formerly known as ‘platelet dust’ were discovered by Wolf in 1967 
(Wolf, 1967). Over the past decades, MP have been previously considered only as an 
innate cell residues or a cell by-products of activated cells (Distler et al., 2005). 
Physiologically, they are virtually released from almost all cell types into the 
extracellular space during cell growth, cell activation, or apoptosis (Spencer et al., 
2018). Microparticles are also released by cells in response to pathological or stress 
conditions such as oxidative stress, sheer stress (Burnouf et al., 2015), and hypoxia 
(Chen et al., 2013). Shedding of MP in vitro may be enhanced by certain stimuli 
including calcium ionophore, histamine (Cerri et al., 2006), endotoxin (Li et al., 2010), 
and cytokines (Liu et al., 2007).  
 
In normal individuals, MP are found at a very low level (Albert et al., 2018), reflecting 
a normal physiological process (Zhou et al., 2015). Recently, numerous studies have 




haemostasis and inflammation (Mooberry and Key, 2016; Suades et al., 2015). 
Elevated number of circulating MP has been observed in many disease states 
particularly in autoimmune disease, cardiovascular disease, and thrombosis (Piccin et 
al., 2007). For instance, CD11a+ MP derived from leucocytes have been detected in 
the early stage of acute coronary syndrome (ACS) at increasing level (Chironi et al., 
2006), while increased level of platelet-derived MP has been correlated with stroke, 
sepsis, and deep vein thrombosis (Hoyer et al., 2010). 
 
 
1.4.2 Origin, features, and formation of microparticles  
Microparticles are originated from various types of eukaryotic cells including blood 
cells such as erythrocytes and leucocytes; platelets, vascular lining cells, cells of the 
tissue and organs (Wang et al., 2014) as well as tumour cells (Distler et al., 2005). 
Thus, MP are heterogeneous in terms of protein composition, size, and density 
depending on their cellular origin (Zubairova et al., 2015). As they can be derived from 
almost all cell types, they can be easily identified in human body fluid such as in blood, 
urine, plasma, and saliva (Street et al., 2012). In healthy humans, the average 
concentration of MP circulating in peripheral blood is within 5 to 50 µg/mL (Hoyer et 
al., 2010). Proportionally, circulating MP are mainly constituted of platelet- and 
megakaryocyte-derived MP, which are 80% of total blood MP (Flaumenhaft et al., 
2009), while MP derived from endothelial cells and leucocytes are approximately 10% 





The structure of MP is less homogeneous, and their membrane consists of 
phospholipids and numerous markers (Figure 1.3). The phenotypic and cytosolic 
characteristics of MP predominantly resemble their origin cell’s identity (Żmigrodzka 
et al., 2016). For example, MP derived from platelets display CD36, CD62P 
(Alkhatatbeh et al., 2011), and CD42b (Flaumenhaft et al., 2009), while MP derived 
from monocytes express CD14 (Bardelli et al., 2012), and CD31 and CD144 for MP 
derived from endothelial cells (Shantsila, 2008). Microparticles also express other 
membrane proteins including PS, tissue factor (TF), and P-selectin glycoprotein 
ligand-1 (PSGL-1) (Halim et al., 2016) on their external membrane.  
 
In addition, MP carry essential cytoplasmic proteins (Choi et al., 2013), nucleic acids 
including DNA, RNA, mRNA , microRNA, and long noncoding RNA (Morello et al., 
2013), as well as lipids and organelles (Mause and Weber, 2010). The genetic contents 
of MP allow them to act as messengers and mediate communication between cells. 
Microparticles convey biomolecules and transmit signal to the surface receptors of 
recipient cells, thus trigger the alteration in their phenotypic expression and cellular 
functions (Valadi et al., 2007). Previously, it has been reported that different 
mechanisms such as cell-to-cell contact or release of signalling mediators permit an 
effective information transmission by MP from the parent cell to the target cells 
(Mause and Weber, 2010). For example, platelet-derived MP may fuse with 
haematopoietic cells and subsequently transfer CD41 antigen expressed on blood 







Figure 1.3: Membrane structure of microparticles derived from monocytes, 
platelets and endothelial cells. The membrane proteins and cytosolic contents of MP 
tend to mirror their origin cells. Monocyte-derived MP express CD14, platelet-derived 
MP express P-selectin, and endothelial cell-derived MP express endothelial cell 










The formation of MP involves two main steps, which are the rearrangement of 
cytoskeleton and externalisation of PS (Said et al., 2018). Usually, the distribution of 
phospholipids on cell membrane is asymmetrical under resting condition. The 
positively charged phospholipids including phosphatidylcholine and sphingomyelin 
are exposed on the lipid bilayer membrane, while the negatively charged phospholipids 
such as PS and phosphatidylethanolamine are located inside the membrane (Piccin et 
al., 2007).  
 
Upon cellular activation, intracellular calcium increases in response to stimuli, thus 
resulting in the activation of calcium-dependent enzymes such as kinase, calpain, and 
gelsolin as well inhibition of phosphatase (Morel et al., 2011a) (Figure 1.4). The 
activation of these enzymes further facilitates the cleavage of cytoskeleton proteins 
(Cohen et al., 2002) including filament, talin, and α-actinin (Nolan et al., 2008). In 
addition, the calcium influx consequently alters the function of the three important 
cytosolic enzymes, namely flippase, floppase, and scramblase (Burger et al., 2013). 
The activation of floppase and scramblase by calcium influx depends on adenosine 
triphosphate (ATP). Floppase governs the translocation of PS and 
phosphatidylethanolamine rapidly to the outer leaflet and scramblase mediates 
phospholipid randomisation down the concentration gradient, while internalising 
phosphatidylcholine and sphingomyelin (Bevers and Williamson, 2010). These 
enzymatic actions subsequently disrupt the membrane asymmetry. As the action of 
flippase and aminophospholipid translocase to maintain the normal asymmetric 







Figure 1.4: The formation of microparticles. Cell activation by stimuli results in 
activation of caspases, and binding of GTP to Rho kinase, which leading to 
phosphorylation of myosin light-chain kinase (MLCK). Cell activation also results in 
increased calcium influx within cells, leading to activation of kinase, calpain, and 
gelsolin and inhibits phosphatase, thus resulting in cytoskeleton reorganisation. 
Calcium influx further activates scramblase and floppase, as well as inhibits flippase 
and translocase, and consequently facilitating the externalisation of PS. (Modified 












the inner leaflet is prevented (Daleke, 2003; Herring et al., 2013). Thus, phospholipid 
imbalance, cytoskeleton proteolysis, and weakening of protein fibrils favour the 
cellular blebbing, which ultimately leads to the shedding of MP (Burnier et al., 2009). 
 
Cell activation may subsequently induce the activation of Rho by caspase-2 (Sapet et 
al., 2006) and caspase-1 cleavage (Coleman et al., 2001) which further initiates the 
conversion of guanosine diphosphate (GDP) to guanosine triphosphate (GTP). 
Subsequently, the binding of GTP to Rho promotes the C-terminal cleavage of Rho-
associated kinase I (ROCK-I) (Coleman et al., 2001) and ROCK-II (Sapet et al., 2006), 
thus leading to an increase in the phosphorylation of myosin light-chain kinase 
(MLCK). The phosphorylation activity in turns facilitates the detachment of 
cytoskeleton from the membrane and release of MP (Distler et al., 2005). 
 
 
1.4.3 Methods of microparticle detections  
Microparticles express PS and other surface antigens on their membrane. Their mother 
cell–mimicking property allows for the subpopulation identification as well as 
determination of cellular origin of MP (Barteneva et al., 2013). Minimal information 
for studies of extracellular vesicles 2018 (MISEV2018) has provided a basic guideline 
in characterising MP including characterisation of protein membrane, cytosolic 
components such as protein and genetic materials, soluble extracellular proteins 
including cytokines and growth factors, as well as structural details of MP (Théry et 





Flow cytometry is the most widely used method to identify MP population. Flow 
cytometry is a fast method and provides high-resolution of quantitative and qualitative 
data based on single MP. This convenient method permits the analysis of large 
numbers of sample in a short time (Burger et al., 2013). The use of flow cytometry 
allows for detection of MP population by double staining with Annexin-V and antigen 
of interest (Nomura et al., 2008), thus defining the origin of MP. Annexin-V, which 
binds to PS, enables the detection of MP. In addition, assessment of light scattering 
intensity assists in size determination of MP (Gradziuk and Radziwon, 2017), while 
total amount of MP can be counted using commercial beads (Lacroix et al., 2010). 
Flow cytometry is also able to assess the protein content of MP, which is expressed as 
molecular mass units (Jy et al., 2004).    
 
Currently, the detection of MP is ascertained by Western blotting, which mainly 
assesses the total amount of protein content in MP. Western blotting can identify the 
molecular weight of MP proteins since they are separated based on their molecular 
weight on a gel electrophoresis (Coumans et al., 2017a). Western blotting are also 
capable of specifying the origin of MP as it provides information regarding the specific 
antigen expressions on MP (Barteneva et al., 2013; Berezin, 2015). By using specific 
primary antibodies that directly target the antigens expressed on MP, Western blotting 
is useful in characterising MP. However, the use of Western blotting in translational 
studies is limited as it requires MP in a large quantity (Street et al., 2012). This method 
is also unable to measure the size of MP (Barteneva et al., 2013).  
 
Electron microscopy techniques such as scanning electron microscopy (SEM), 




microscopy were used to assess the morphology and size of individual MP (Théry et 
al., 2018). On ultrathin sections, MP appear as single vesicles displaying 
heterogeneous internal content (Barteneva et al., 2013), with the diameter ranging 
from 0.02 to 0.04 µm (Duarte et al., 2012) and 0.3 to 0.7 µm (Burger et al., 2011), 
while larger MP of 1 µm in size are characterised using freeze-fracture and SEM (Rood 
et al., 2010). Both SEM and TEM are unable to provide data on protein content and 
genetic information of MP. In addition, the cellular origin of MP could not be 
determined as well by microscopy (Barteneva et al., 2013).  
 
Another detection method that can be used to characterise MP is by ELISA, a simple 
and reproducible method which relies on the basis of MP binding to monoclonal 
antibodies conjugated with fluorescein. ELISA provides quantitative assessment of 
specific molecules of MP such as membrane and cytosolic proteins as well as cytokine 
production (Théry et al., 2018). This method also permits the processing of a large 
number of samples at one time (Gradziuk and Radziwon, 2017), allowing for 
simultaneous repetition of experiments. MP detection using ELISA usually involves 
the recognition and measurement of phospholipids on MP. Nonspecific binding of 
Annexin-V to other antigens may lead to unreliable results, thus limiting the efficiency 
of this method (Lacroix et al., 2010). However, ELISA is unable to measure the size 
of MP and the presence of insoluble antigens, as the antibodies only bind to soluble 






1.4.4 The functions of microparticles 
Microparticles play a significant role in cell communication in vivo by transmitting 
and exchanging information between cells (Hoyer et al., 2010). Microparticles act as 
signalling molecules since they possess membrane signalling proteins and lipids 
(Figure 1.5). Surface ligands expressed on MP allow direct stimulation of target cells. 
For example, platelet-derived MP express CD41 and CD62P (P-selectin) on their 
surface, which permit their attachment on endothelial cells, thus transmitting the 
signals and resulting in endothelial cell activation (Distler et al., 2005). Microparticles 
also contain growth factors such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF) as well as express bioactive lipids such as sphingosine-
1-phosphate, which promotes proliferation of endothelial cells and tissue regeneration, 
particularly during morphogenesis (Varon and Shai, 2015). Meanwhile, proteins on 
MP originated from lymphocytes facilitate the differentiation of haematopoietic cells 
to megakaryocytes (Hugel et al., 2005), while  glycoprotein IIb/IIIa expressed on MP 
derived from platelets enhance haematopoietic stem and progenitor cells engraftment 
(Janowska-Wieczorek et al., 2001). 
 
Additionally, MP are involved in cell interaction by transferring receptor protein from 
a cell to other cells. Platelet-derived MP transfer adhesion molecules from platelets to 
endothelial cells as well as tumour cells, thus promoting the adhesion of leucocytes to 
endothelial cells (Janowska‐Wieczorek et al., 2005). A previous study has reported 
that the transfer of CCR5 by monocyte-derived MP increases the susceptibility of cells 






Figure 1.5: The function of microparticles. Microparticles are involved in cellular 
interaction by transferring information via surface molecules, transfer of protein 

















It has been previously demonstrated that the transfer of CCR5 receptor by MP to cells 
that lack of this chemokine co-receptor, including endothelial cells and 
cardiomyocytes, results in increased cell vulnerability towards virus infection (Mack 
et al., 2000). Therefore, this suggests that MP are actively participate in pathological 
conditions. 
 
Microparticles also play a role in RNA exchange between cells. For example, MP 
derived from endothelial progenitor cells activate angiogenic programme within 
endothelial cell in vitro by transferring mRNA (Deregibus et al., 2007). Subsequently, 
angiogenic activity promotes the proliferation and survival of endothelial cells as well 
as formation of new capillary (Hoyer et al., 2010). The interaction between endothelial 
cells with α4 and β1 integrins expressed on MP that are involved during MP 
incorporation into endothelial cells may be inhibited by the addition of RNase 
(Deregibus et al., 2007), thus confirming the role of MP as exchange vectors of 
mRNA. Termination of MP incorporation into endothelial cells results in the failure of 
MP-mediated RNA transfer and subsequently attenuates the process of angiogenesis 
both in vitro and in vivo.  
 
Previously, recovery of hypoxia-injured myocardial tissue has been observed after 
stem cell infusion, in which MP have been suggested to transfer healthy mitochondria 
to hypoxia-injured myocardial tissues (Mack, 2006), thus improving tissue 
regeneration. Meanwhile, it has been reported that the ability of mitochondria-depleted 
MP to induce IL-8, ICAM-1, and VCAM-1 expression in endothelial cells was 
significantly reduced compared to control (Puhm et al., 2019). Thus, this finding 




1.5 Monocytic microparticles (mMP) 
Monocytic microparticles (mMP) are shed from the plasma membrane of monocytes 
in response to stimulation. Similar to other MP, mMP display similar surface antigens 
to monocytes. Other than CD14, mMP also express other myeloid markers including 
CD11a, CD11b, and HLA-DR (Takeshita et al., 2014). Monocytic MP also express 
TF and PSGL-1 on their surface. As mMP are released from monocytes, the population 
of monocytes in peripheral blood itself reflects the quantity of circulating mMP (Halim 
et al., 2016).   
 
Monocytic MP may carry different characteristics in vivo as well as in vitro depending 
on the type of stimuli. For instance, mMP released upon LPS stimulation express 
higher PS compared to mMP derived from stimulation by P-selectin–Ig chimera 
(Bernimoulin et al., 2009). Monocytic MP derived from LPS-stimulated monocytes 
consist of nuclear proteins and mitochondria, which are essential for energy pathways 
and metabolism. In addition, leukocyte-associated immunoglobulin-like-receptor-1 
(LAIR-1) is only expressed on mMP following stimulation with P-selectin–Ig chimera 
(Schindler et al., 2016). These differences in terms of membrane protein composition 








1.5.1 The role of mMP in inflammation 
The association of mMP with inflammation has been reported previously (Hugel et al., 
2005). Apart from participating in cellular interaction, mMP may contribute in 
inflammation by enhancing the release of numerous inflammatory cytokines and 
chemokines by immune cells (van Hezel et al., 2017) as well as up regulating the 
expression of adhesion molecules by endothelial cells (Cloutier et al., 2013). 
 
Vascular endothelial cells of the blood vessels are one of the effector cells of mMP 
(Lovren and Verma, 2013). During inflammation, the pro-inflammatory properties of 
mMP are mainly exerted on endothelial cells. Monocytic MP regulate inflammatory 
response in endothelial cells via activation of extracellular signal-regulated kinase 1/2 
(ERK1/2) and phosphorylation of NF-κB pathway (Cerri et al., 2006; Puddu et al., 
2010). In vitro, mMP may promote pro-inflammatory activity of endothelial cells by 
fusion and internalisation of mMP containing IL-1β and inflammasome via PS, which 
are expressed on mMP (Wang et al., 2011). Protein ligands such as PSGL-1 and P-
selectin that are expressed on mMP permit and increase their adhesiveness to adhesion 
molecules on endothelial cells (Bernimoulin et al., 2009). Subsequently, binding of 
mMP to endothelial cells induces the release of TNF-α, IL-1β, IL-6, IL-8, and MCP-1 
by endothelial cells (Neri et al., 2011), thus further enhancing inflammation. Together 
with pro-inflammatory cytokines, mMP enhance ICAM-1, VCAM-1, and E-selectin 
expression by endothelial cells, which are important for leucocyte chemotaxis (Lovren 
and Verma, 2013). Additionally, mMP release caspase-1 in response to sepsis, thus 
leads to increased nitrosative stress through PI3 kinase and ERK1/2 pathway 
(Mastronardi et al., 2011), as well as induced apoptosis in endothelial cells (Mitra et 




production and elimination of reactive nitrogen species (RNS), and mMP may increase 
the production of nitrogen oxide (NO), thus inducing nitration of proteins and cell 
damage (Mastronardi et al., 2011).  
 
Additionally, the interaction between mMP and endothelial cells consequently induces 
endothelial vesiculation, resulting in the release of endothelial microparticles (eMP). 
The shedding of eMP results from the activity of pro-inflammatory factors, including 
growth factors such as vascular endothelial growth factors (VEGF) (Neves et al., 2019) 
and cytokines such as IL-6 and TNF-α, which are released following mMP–endothelial 
cell interaction (Deng et al., 2017). In turn, eMP elicit a pro-inflammatory response in 
endothelial cells by enhancing adhesion molecule expression on endothelial cells, thus 
resulting in monocyte adhesion (Jansen et al., 2017). 
 
Monocytic MP may exert an autocrine effect on their origin monocytes. The 
inflammatory response of monocytes contributed by mMP is mainly through the lipid 
fraction on mMP membrane, which binds to and activates TLR 4 on monocytes 
(Thomas and Salter, 2010). The interaction of mMP with monocytes subsequently 
induces the release of pro-inflammatory cytokines IL-1β (Wang et al., 2011), 
superoxide anion (O2
−) production, and activation of NF-κB pathway in monocytes 
(Bardelli et al., 2012), which may exacerbate the inflammatory condition. Monocytic 
MP also facilitate monocyte–endothelial cell interaction, which is the initial step in 
vascular inflammation. During inflammation, mMP support the attachment of 
monocytes to ICAM-1 expressed on activated endothelial cells by transferring 
oxidised phospholipids, RANTES, or caspase-3 to endothelial cells (Edrissi et al., 




macrophage antigen 1 (MAC-1) in monocytes (Batool, 2013). These processes favour 
transmigration and recruitment of activated leucocytes in the vascular intima during 
inflammation. Subsequent leucocyte infiltration at the inflammatory site eventually 
leads to the development of inflammatory condition (Puddu et al., 2010). 
 
On the other hand, the anti-inflammatory effect of mMP may be seen through the down 
regulation of pro-inflammatory activity by cytokines at the early inflammatory stage. 
For instance, mMP hamper the activation of monocytes by inhibiting TNF-α, IL-8, and 
IL-6 secretion, as well as induce the release of transforming growth factor-β1 (TGF-
β1) and IL-10 (Gasser and Schifferli, 2004). Monocytic MP also amplify the 
expression of peroxisome proliferator-activated receptor γ (PPAR-γ) protein in 
monocytes (Neri et al., 2011) to reduce inflammatory activity. PPAR-γ protein 
attenuates the signalling pathway through the restriction of NF-κB activity, leading to 
down regulation of adhesion molecule expression on the target cells (Halim et al., 
2016; Sahler et al., 2014). Besides that, Annexin A1, an anti-inflammatory 
glucocorticoid-regulated protein that is encapsulated within mMP, contributes to the 
immunosuppressive effect of mMP (Dalli et al., 2008). The resolution mechanisms of 
inflammation modulated by Annexin A1 involve the suppression of pro-inflammatory 
molecules release, limiting leucocyte diapedesis, and initiation of the conversion of 
monocytes and macrophages into a pro-resolving phenotype (Sugimoto et al., 2016) 
such as CD206 (Lee et al., 2002) to restore tissue homeostasis. Overall, mMP exert a 
negative feedback loop of anti-inflammatory effect through the inhibition of signalling 




1.5.2 The role of mMP in coagulation 
The close interaction of inflammation and coagulation is crucial for the immune 
system. Blood clotting activity at the site of inflammation is crucial in preventing 
dissemination of infection through the bloodstream. One of the possible mechanisms 
of the coagulation cascade activation by inflammation is via the involvement of 
surrounding MP (Foley and Conway, 2016). It has been reported that mMP may exert 
dual function in coagulation either as a procoagulant or as an anticoagulant (Khan et 
al., 2016; Shustova et al., 2017).  
 
The potential procoagulant properties of mMP are mainly contributed by TF and PS, 
which are abundantly expressed on mMP. TF is an initiator of coagulation process 
since it acts as a receptor for FVII/VIIa (Mooberry and Key, 2016). In vivo, the binding 
of TF with FVII/VIIa forms a TF–FVIIa complex, inducing the activation of FX and 
FIX (Mackman et al., 2007) (Figure 1.6). Activated FX and FIX further trigger the 
activation of downstream coagulation cascade, which results in generation of thrombin 
(FIIa). Subsequently, thrombin promotes the conversion of fibrinogen into fibrin and 
initiates the aggregation of platelets for blood clot formation (Choi and Levi, 2006). 
Accumulation of fibrin also increases the density and strengthens the fibrin network, 
thus resulting in resistance to fibrinolysis (Aleman et al., 2011). Additionally, the 
interaction between PSGL-1 on mMP with P-selectin on platelets may cause mMP to 
bind to and transfer TF to platelets. It has been previously demonstrated that TF-





Figure 1.6: The role of mMP in coagulation. Monocytic MP play a role in 
coagulation by acting as a procoagulant via tissue factor (TF) activity or as an 
anticoagulant via tissue factor pathway inhibitor (TFPI), protein C, or protein S. 











development in preclinical models (Engelmann and Massberg, 2013; Muller et al., 
2003). Elevated number of circulating TF-expressing mMP were reported in sickle cell 
disease, thromboembolism, malignancy, sepsis, and atherosclerosis (Ye et al., 2012). 
 
Meanwhile, PS increases the procoagulant activity of mMP and aids in the formation 
of blood clot. Negatively charged PS on mMP may interact with γ-carboxyglutamic 
acid (GLA) domain in the clotting protein (Owens and Mackman, 2011). This 
interaction facilitates the recruitment of protein cascade FVII, FIX, FX, and 
prothrombin. A previous study has shown that defect in the production of PS-
expressing MP in patients with Scott syndrome results in high bleeding tendency. A 
high level of PS-expressing MP has been observed in patients with IgA nephropathy 
and associated with intraglomerular coagulation (He et al., 2015). In addition, PS-
expressing MP have been related with hypercoagulable state in patients suffering from 
colon cancer (Zhao et al., 2016). Meanwhile, inhibition of PS with lactadherin results 
in prolonged clotting formation, reduced formation of fibrin, and inhibition of 
thrombin production (Guo et al., 2018), thus indicating the direct involvement of PS 
in coagulation.  
 
Besides possessing procoagulant properties, mMP induce a negative feedback loop in 
coagulation through fibrinolytic mechanism or anticoagulation (Owens and Mackman, 
2011) through tissue factor pathway inhibitor (TFPI), thrombomodulin (TM), 
activated protein C, and protein S. Briefly, TFPI is a primary inhibitor of coagulation 
cascade that prevents procoagulant response at the early phases of the extrinsic 
pathway. TFPI blocks the activity of FXa by forming TFPI–FXa complex in vivo 




TF–VIIa complex and prothrombinase in an FXa-dependent manner (Wood et al., 
2014). Consequently, this activity modulates the downstream pathway of coagulation 
cascade and thus prevents blood clot formation. During FXa inhibition by TFPI, 
protein S acts as a cofactor of TFPI that enhances the binding of TFPI to FXa (Hackeng 
et al., 2006).  
 
In addition, TM, a transmembrane molecule regulates anticoagulant response by 
binding to thrombin, forming thrombin–TM complex. This complex simultaneously 
activates protein C to form activated protein C (APC) (Dahlbäck and Villoutreix, 
2005). Activated APC further cleaves and transforms FVIIa and FVa into inactive 
forms (Ezihe-Ejiofor and Hutchinson, 2013). With the aid of protein S, TM and APC 
further limit the formation of thrombin by directly inducing prothrombinase inhibition, 
thus preventing the formation of blood clot.   
 
 
1.6 The role of mMP in disease 
Monocytic MP contain various cellular proteins and genetic molecules that allow them 
to participate in pathological settings. A high number of circulating mMP is often 
associated with disease pathogenesis and severity (Souza et al., 2015). Particularly, 
mMP actively play a role in inflammation and thrombotic events such as in 
cardiovascular disease, autoimmune disease, and metabolic disorders. 
 
Monocytic MP are involved in the progression of autoimmune diseases such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The presentation 




conditions such as pronounced systemic inflammation or infection (Shao, 2016). In 
SLE patients, elevation of type 1-interferon (IFN) production and interferon-inducible 
gene expression have been observed, in which the activation of IFN pathway may 
increase the severity of SLE (Crow et al., 2015). Monocytic MP interact with IFN-α, 
thus leading to monocyte activation as well as IL-6, IL-8, and TNF-α release (Nielsen 
et al., 2014). This interaction consequently results in worsening of inflammation in 
SLE patients. In RA patients, mMP in the synovial fluid induces the release of IL-1, 
IL-6, IL-8, and MCP-1; and synoviocyte activation which may cause synovitis 
(Viñuela-Berni et al., 2015). Activation of synovial fibroblasts by mMP also leads to 
the production of matrix metalloproteinases (Distler et al., 2005) that degrade 
extracellular matrix protein, thus causing cartilage and joint destructions (Araki and 
Mimura, 2017).     
 
Elevated levels of mMP and changes in their phenotypes have been observed in 
metabolic disorders such as atherosclerosis and familial hypercholesterolaemia (FH). 
Monocytic MP facilitate plaque formation and immune cell accumulation at the blood 
vessel of murine models (Hoyer et al., 2012), thus increasing the risk of thrombosis. 
Patients suffering from FH, a disease associated with high level of low-density 
lipoprotein (LDL), are at higher risk of atherosclerosis development (Halim et al., 
2016). The increase of mMP in FH patients is related to LDL cholesterol oxidisation 
via CD36-dependent mechanism (Hjuler Nielsen et al., 2015). Thus, mMP may 





1.7 Rationale of the study 
Microparticles have gained interest as they have been reported as important player in 
inflammation, coagulation, and alteration of endothelial cell functions. Previous 
studies on MP were mainly performed on MP derived from erythrocytes (Said et al., 
2018), platelets (Zhao et al., 2016), lymphocytes (Tahiri et al., 2016), and endothelial 
cells (Deng et al., 2017; Herring et al., 2013). The level of MP has been reported to 
increase in number during pathological conditions particularly during inflammation, 
reflecting their function as potential biomarkers. However, information regarding the 
interaction between MP derived from monocytes and endothelial cells is limited. 
Although several studies have been performed on mMP, most of them used monocytic 
cell lines instead of primary monocytes (Wang et al., 2011; Wen et al., 2014). As MP 
with different characteristics may arise from different cell types, theoretically, mMP 
derived from human blood may exhibit different phenotypic and functional properties 
compared to those derived from monocytic cell lines (Halim et al., 2016). Therefore, 
this study was carried out to characterise surface antigen expression of mMP derived 
from human monocyte subsets and their potential functions in blood coagulation as 
well as in endothelial cell activations.  
 
This study provides preliminary data on mMP surface phenotypes, coagulation 
potential, and activation of endothelial cells by mMP derived from human monocytes. 
Phenotypic information of mMP may be useful as a potential biomarker in diagnosis 
and prognosis of inflammatory conditions. Additionally, a better understanding on 
how mMP regulate the coagulation pathway and endothelial cell activation permits 




diseases. We hypothesise that mMP derived from LPS-stimulated human monocytes 





1.8.1 General objective 




1.8.2  Specific objectives 
1. To characterise cell surface phenotypes of mMP derived from LPS-stimulated 
whole monocytes, CD14+ monocytes, and CD16+ monocytes. 
2. To assess coagulation potential of mMP derived from LPS-stimulated 
monocytes. 
3. To measure the expression of adhesion molecules ICAM-1 and VCAM-1 by 
endothelial cells following culture with mMP. 
4. To assess cell surface phenotypes of endothelial microparticles (eMP) derived 







CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 Experimental design 
This study was performed as shown in Figure 2.1. Briefly, blood were collected from 
healthy donors followed by PBMC isolation. Then, whole monocytes were further 
isolated from PBMC using Pan Monocytes Isolation Kit. CD14+ monocytes and 
CD16+ monocytes were then purified from the whole monocytes using CD16 Isolation 
Kit. Whole monocytes, CD14+ monocytes and CD16+ monocytes were further cultured 
in the presence or absence of LPS for 18 hours. Monocytic MP were isolated from the 
culture supernatants by ultracentrifugation before being assessed for their surface 
phenotypes by flow cytometry and coagulation property by Start4 coagulometer. 
Monocytic MP were also cultured with HUVEC. The level of ICAM-1 and VCAM-1 
expressions by endothelial cells upon culture with mMP was measured by real-time 
PCR. Meanwhile, the expression of CD31 on HUVEC and eMP following culture with 






































Figure 2.1: Flow chart of the study. Blood was collected from healthy donors. (1) 
Whole monocytes, (2) CD14+ monocytes, and (3) CD16+ monocytes were cultured in 
the presence or absence of LPS for 18 hours. Cell surface phenotypes of monocyte 
subsets and mMP were assessed. Prothrombin time and endothelial cell activation were 
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2.2 Materials  
2.2.1 List of chemicals and reagents 
All reagents used in this study were listed in Table 2.1. 
 
Table 2.1: List of chemicals and reagents 
Reagents Manufacturer 
0.25% Trypsin-1 mM EDTA Nacalai Tesque, Japan 
0.4% Trypan blue solution Sigma Aldrich, UK 
10X Annexin-V binding buffer Becton Dickinson, USA 
2% Gelatine Type B solution Sigma Aldrich, UK 
2-mercaptoethanol GIBCO, USA 
6X RNA loading dye ThermoFisher Scientific, USA 
Acetic acid Sigma Aldrich, UK 
Agarose powder Vivantis, Malaysia 
Bovine serum albumin (BSA) Amresco, USA 
Dimethyl Sulfoxide (DMSO) Fisher Scientific, USA 
Endothelium cell growth medium 2 PromoCell, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, UK 
Fetal bovine serum (FBS) Sigma Aldrich, UK 
Ficoll-Paque PLUS solution GE HealthCare, USA 








Non-essential amino acid GIBCO, USA 
Normal pooled plasma Diagnostica Stago, USA 
Penicillin-streptomycin with glutamine 
(PSG) 
GIBCO, USA 
Phosphate-buffered saline (PBS) Amresco, USA 
Primers (GAPDH, ICAM-1, VCAM-1) Integrated DNA Technologies, USA 
RiboRuler High Range RNA ladder ThermoFisher Scientific, USA 
Rosewell Park Memorial Institute-1640 
(RPMI-1640) 
Sigma Aldrich, UK 
Sodium azide Sigma Aldrich, UK 
Sodium Pyruvate GIBCO, USA 






















2.2.2 List of antibodies 
All antibodies used in this study are listed in Table 2.2.  
 
Table 2. 2: List of antibodies 
Antibodies Manufacturer 
Allophycocyanin (APC) Mouse Anti-
Human CD16 (Clone: B73.1) 
BD Bioscience, USA 
Fluorescein isothiocyanate (FITC) 
Annexin-V  
BD Bioscience, USA 
Phycoerythrin (PE) Mouse Anti-Human 
CD14 (Clone: MɸP9) 
BD Bioscience, USA 
PE Mouse Anti-Human CD142 (Clone: 
HTF-1) 
Miltenyi Biotech, Germany 
PE Mouse Anti-Human IgG1 (Clone: 
X40) 
BD Bioscience, USA 
Peridinin chlorophyll A protein 

















2.2.3 List of commercial kits 
All commercial kits used in this study are listed in Table 2.3.  
 
Table 2. 3: List of commercial kits 
Commercial kits Manufacturer 
BD CompBeads Anti-Mouse Ig, ĸ/ 
Negative Control Compensation 
Particles Set 
BD Bioscience, USA 
BD TruCount beads BD Bioscience, USA 
LUNA® Universal One-Step RT-qPCR 
Kit  
New England BioLabs, USA 
MACS CD16 Isolation Kit, Human  Miltenyi Biotec, USA 
MACS Pan Monocytes Isolation Kit, 
Human  
Miltenyi Biotec, USA 
Mini & MidiMACSTM Starting Kit Miltenyi Biotec, USA 
RNeasy Mini Kit  Qiagen, Germany 
ToxinSensor Chromogenic LAL 










2.2.4 List of equipment 
All equipment used in this study are listed in Table 2.4.  
 
Table 2. 4: List of equipment 
Equipment Manufacturer 
Applied Biosystems 7500 RT-PCR 
machine 
Applied Biosystem, USA 
Autoclave sterilizer Amerex Instruments, USA 
BD FACS Canto II Flow Cytometer  BD Bioscience, USA 
CO2 incubator Binder, Germany 
Gel DocTM XR+ imaging system Bio-Rad, USA 
Inverted microscope  Leica, Germany 
Mechanical pipette  Sartorius, Germany 
Mikro 22 R Centrifuge  Hettich Zentrifugation, Germany 
NanoDrop ND-2000 Spectrophotometer  Thermo Scientific, USA 
Neubauer counting chamber  Marienfeld, Germany 
Start® 4 semi-automated coagulometer  Stago, USA 
Universal 320 centrifuge  Hettich  Zentrifugation, Germany 
Vortex mixer 
ERLA Technologies (M) Sdn Bhd, 
Malaysia 









2.2.5 List of softwares 
All softwares used in this study are listed in Table 2.5.  
 
Table 2. 5: List of softwares 
Softwares  Manufacturer 
ABi 7500 Real Time-PCR software  AB system, USA 
FCS Express 5 Flow Research Edition De Novo, USA 
Prism 7, Academic use Graphpad, USA 
Image LabTM software  Bio-Rad, USA 





2.3.1 Preparation of sera 
One bottle of frozen fetal bovine serum (FBS) and heat-inactivated frozen human AB 
serum were thawed by heat-inactivated at 56°C for 30 minutes with gentle agitation. 







2.3.2 Complete AB medium  
Rosewell Park Memorial Institute (RPMI)-1640 was mixed with 10% human AB 
serum, 1X penicillin-streptomycin-glutamine, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 10 mM HEPES buffer, and 50 µM 2-mercaptoethanol. The 
media was thoroughly mixed and used immediately. 
 
 
2.3.3 Endothelial Cell Growth Medium 2  
Endothelial Cell Growth Medium 2 contains 2% fetal calf serum (FCS), 5 ng/mL 
epidermal growth factor, 10 ng/mL fibroblast growth factor, 20 ng/mL insulin-like 
growth factor (Long R3 IGF), 0.5 ng/mL vascular endothelial growth factor 165, 1 
µg/mL ascorbic acid, 22.5 µg/mL heparin, 0.2 µg/mL hydrocortisone, and 1% 
penicillin-streptomycin. The medium was used immediately for cell maintenance. 
 
 
2.4 Buffers and reagents 
2.4.1 Preparation of 1X phosphate-buffered saline (PBS) 
PBS tablet was dissolved in distilled water in a ratio of 1:100 mL. The pH of the buffer 






2.4.2 Preparation of 70% ethanol 
Ethanol 70% was prepared by mixing absolute ethanol in a ratio of 3:1 with distilled 
water. The solution was stored at room temperature until used. 
 
 
2.4.3 Preparation of magnetic-activated cell sorting (MACS) buffer 
Magnetic-activated cell sorting (MACS) buffer was prepared by mixing 1X PBS with 
0.5% bovine serum albumin (BSA), and 2 mM EDTA. The pH of the buffer was 
adjusted to 7.2 using 1 M HCl and filtered using 0.22 µm filter. The MACS buffer was 
stored at 2 - 8°C until used. 
 
 
2.4.4 Preparation of fluorescence-activated cell sorting (FACS) buffer 
Fluorescence-activated cell sorting (FACS) buffer was prepared by adding 0.5% BSA 
and 0.05% sodium azide into 1X PBS. The solution was filtered using 0.22 µm filter 
and stored at 2 - 8°C until used. 
 
 
2.4.5 Preparation of 1X binding buffer 
Binding buffer (10X) contains sterile 0.1 M HEPES (pH 7.4), 1.4 M NaCl, and 25 mM 
CaCl2 solution. To prepare 1X binding buffer, binding buffer stock of 10X 
concentration was diluted in a ratio of 1:10 with distilled water. The solution was 





2.4.6 Preparation of 1X Tris Acetate-EDTA (TAE) buffer 
Tris acetate-EDTA (TAE) buffer was prepared by dissolving 20 mM Tris-base, 1mM 
EDTA, and 40 mM acetic acid in distilled water. The pH of the buffer was adjusted to 
8.3 using 1 M HCl and stored at room temperature.  
 
 
2.4.7 Dilution of lipopolysaccharides (LPS) 
One mg of lyphophilised lipopolysaccharides (LPS) powder from Escherichia coli 
O26:B6 was initially reconstituted in 1 mL PBS as recommended by the manufacturer 
to make up 1 mg/mL LPS of stock solution. LPS was then diluted in 1X PBS to the 
final concentration of 10 µg/mL. Reconstituted stock solutions were dispensed at 500 
µL into microcentrifuge tubes and stored at -20°C until used. 
 
 
2.5 Methods  
2.5.1 General cellular methods 
2.5.1(a) Autoclaving  
Unless otherwise stated, all heat-resistance apparatus, equipment, appropriate 







Unless otherwise indicated, centrifugation of blood sample was performed at 544 × g 
for 20 minutes at 25°C for the purpose of PBMC isolation. All washing steps for 
PBMC, whole monocytes, CD14+ monocytes, and CD16+ monocytes were performed 
at 544 × g for 5 minutes at 25°C. All washing steps for HUVEC were performed at 
220 × g, 25°C for 3 minutes. Samples for flow cytometry analysis were centrifuged at 
1,200 × g for 5 minutes at 25°C followed by ultracentrifugation of supernatants at 
20,000 × g for 60 minutes at 4°C for MP recovery.  
 
 
2.5.1(c) Assessment of cell viability 
Cell viability of PBMC, monocytes, CD14+ monocytes, CD16+ monocytes and 
HUVEC were assessed using haemocytometer. Cells were mixed with 0.4% Trypan 
blue in a ratio of 1:1. Ten µL of the mixture was loaded onto a hemocytometer counting 
chamber and live cells were counted by Trypan blue exclusion. Cell concentration and 
percentage of cell viability were calculated using the following formula: 
 
     Concentration of   =    Total number of viable cells    x (Dilution factor x 104) 
      cells (cell/ mL)              Number of grid squares                                               
 
     Cell viability (%) =       Total number of viable cell         





2.5.1(d) Assessment of cell morphology 
The morphology of all cells during cell maintenance as well as before and after culture 




2.5.1(e) Determination of cell yield  
Cell yield was calculated to determine the efficacy of cell separation of monocytes, 
CD14+ monocytes, and CD16+ monocytes. The isolation yield was counted by using 
the following formula:  
 
 
Isolation yield =             Number of cells after isolation         
                                Number of cells before isolation in PBMC 
 
 
2.5.1(f) Determination of cell purity 
The purity of isolated whole monocytes, CD14+ monocytes, and CD16+ monocytes 
was evaluated by staining with appropriate antibodies. The cell populations were then 








2.5.1(g) Determination of cell recovery rate 
Cell recovery rate was assessed after cell thawing and cell isolation process. For cell 
recovery rate after cell thawing, the number of viable cells before freezing and after 
thawing was counted and cell recovery rate was calculated using the following 
formula:  
 
Cell recovery =          Number of viable cells after thawing         
                                  Number of viable cells before freezing 
 
To calculate cell recovery rate after cell isolation process, PBMC, whole monocytes, 
CD14+ monocytes and CD16+ monocytes were stained with appropriate antibodies 
before being analysed using flow cytometry. Cell recovery rate after cell isolation 
process was calculated using the following formula: 
 
           Percentage of positively stained cells 
    after isolation         
                        Percentage of positively stained cells  









2.5.2 Cell isolation  
2.5.2(a) Isolation of peripheral blood mononuclear cell (PBMC)  
Blood was collected from healthy donors with appropriate informed consent as 
approved by the Research Ethics Committee (Human) USM 
(USM/JEPeM/15040128). Blood was collected into EDTA anticoagulant tubes via 
standard venipuncture in 30 – 50 mL. Ten ml blood was transferred into a 50 mL tube 
and was diluted in a ratio of 1:2 with 1X PBS. Blood was gently mixed and slowly 
underlaid with 10 mL Ficoll-Paque PLUS solution into the bottom of the blood 
mixture. The blood mixture was centrifuged at 25°C, 544 × g without brakes for 20 
minutes. PBMC were carefully collected from the buffy coat by using pasteur pipette 
into a 50 mL tube. PBS was added into the tube containing PBMC up to 50 mL. Cell 
count was performed using hemocytometer and cells were centrifuged at 25°C, for 10 
minutes at 544 × g. Supernatants were discarded and cell pellets were resuspended in 
complete AB medium or MACS buffer. 
 
 
2.5.2(b) Isolation of whole monocytes  
Unless otherwise stated, whole monocytes will be referred to as monocytes hereafter. 
Isolation of human whole monocytes from PBMC was performed using Pan Monocyte 
Isolation Kit as indicated by the manufacturer. PBMC were resuspended in 40 µL of 
MACS buffer per 107 total cells. Then, PBMC suspensions were stained immediately 
with 10 µL of FcR Blocking reagent and Biotin-Antibody Cocktail per 107 total cells 
followed by incubation for 5 minutes at 2 – 8°C. Subsequently, 30 µL of MACS buffer 




20 µL Anti-Biotin Microbeads per 107 total cells. PBMC suspensions were incubated 
for another 10 minutes at 2 – 8°C before whole monocytes being immunomagnetically 
isolated by using MS or LS column, depending on cell concentration. The MS or LS 
column were initially rinsed with 500 µL or 1000 µL MACS buffer respectively. 
PBMC suspensions were then loaded onto MS or LS column and unlabelled 
monocytes were collected from the negative fraction that passed through the column. 
The column was washed for three times with 500 µL MACS buffer for MS column or 
1000 µL MACS buffer for LS column. 
 
 
2.5.2(c) Isolation of CD14+ monocytes and CD16+ monocytes 
The CD14+ monocyte and CD16+ monocyte subpopulations were further isolated from 
monocytes using CD16 Isolation Kit according to the manufacturer’s instructions 
(Figure 2.2). Monocyte suspensions were centrifuged at 300 × g for 10 minutes at 25°C 
and supernatants were discarded. Cell pellets which consist of monocytes were 
resuspended in 50 µL of MACS buffer per 5 x 107 total cells. Monocyte suspensions 
were subsequently stained with 50 µL of CD16 Microbeads per 5 x 107 total cells prior 
to incubation at 2 – 8°C for 30 minutes. Monocyte suspensions were washed with 1 – 
2 mL MACS buffer per 107 total cells following centrifugation at 300 × g for 10 
minutes at 25°C. Supernatants were discarded and cell pellets were resuspended in 500 
µL MACS buffer up to 108 total cells. To isolate CD14+ monocytes and CD16+ 
monocytes, monocyte suspensions were subjected to magnetic separation method 
using MS or LS column, depending on cell concentration. The MS or LS column were 













Figure 2.2: Isolation of PBMC, whole monocytes, CD14+ monocytes, and CD16+ 
monocytes. PBMC were isolated from human blood followed by isolation of whole 
monocytes. Both CD14+ monocytes, and CD16+ monocytes were further isolated from 
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suspensions being loaded onto MS or LS column. Then, unlabelled CD14+ monocytes 
were collected into a new tube from the negative fraction, which have passed through 
the column. The washing steps with 500 µL MACS buffer for MS column or 1000 µL 
MACS buffer for LS column were performed for three times. The column was then 
placed onto a new tube. Magnetically labelled CD16+ monocytes were then eluted 
immediately from the positive fraction using a provided plunger. 
 
 
2.5.2(d) Culture of human umbilical vein endothelial cells (HUVEC) 
Human umbilical vein endothelial cells (PromoCell, Germany) were cultured in a T25 
or T75 flask coated with 0.2% gelatine type B solution and maintained in complete 
Endothelial Cell Growth Medium 2. The medium was replaced every two to three 
days. All cell washing steps were performed using 1X PBS. Cells were allowed to 
grow in a 37°C, 5% CO2/air atmosphere incubator until 70 – 80% confluent. 
Trypsinisation was performed using 0.25% Trypsin-EDTA for 5 minutes at room 
temperature followed by the addition of an equal volume of medium to neutralise the 
trypsin. Detached cells were centrifuged at 220 × g for 3 minutes at 25°C to pellet the 
cells. Cells were routinely passaged every two to three days and were used between 
the 5th and 10th passage (Liao et al., 2014). 
 
Confluent monolayer of HUVEC in a treated 6-well plate were serum starved for four 
hours prior to culture with 300 µg/mL LPS-stimulated or unstimulated mMP derived 
from whole monocytes for two hours in serum free condition (Wang et al., 2011). 
HUVEC were subsequently trypsinised and centrifuged at 220 × g for 3 minutes at 




1 mL of 1X PBS and centrifuged at 220 × g for 3 minutes at 25°C. Cell pellets were 




2.5.2(e) HUVEC cryopreservation and thawing 
Confluent HUVEC were trypsinised before being centrifuged at 220 × g for 3 minutes 
at 25°C. A cryopreservation solution was prepared by slowly adding 10% dimethyl 
sulfoxide (DMSO) into 90% heat-inactivated FBS. Cell pellets were resuspended 
gently in a cryopreservation solution to the final concentration of 2 × 105 – 5 × 105 
cells/mL. The cell suspensions were dispensed into 1.5 mL cryogenic vials and 
immediately transferred to a -20°C freezer. After 20-30 minutes, the vials were 
transferred to a -80°C freezer for 24 hours before being transferred to a liquid nitrogen 
container (-196°C). 
 
Frozen HUVEC were thawed rapidly in a 37°C water bath for 1 minute. Cells were 
then transferred into 0.2% gelatine type B solution coated cell culture flask containing 
pre-warmed culture medium. The cells were then allowed to attach on a culture flask 
by incubating in a 37°C, 5% CO2/air atmosphere incubator for 24 hours. The medium 






2.5.3 Generation and isolation of microparticles (MP) 
2.5.3(a) Monocytic MP (mMP) 
Whole monocytes, CD14+ monocytes and CD16+ monocytes were cultured in a 96-
well plate at a concentration of 2 × 105 cells/mL in complete AB medium. Cells were 
stimulated with 1 µg/mL LPS from Escherichia coli O26:B6 based on optimization 
and were allowed to grow in an incubator at 37oC in 5% CO2 atmosphere. Following 
18 hours incubation (Wen et al., 2014), cell viability was assessed using Trypan blue 
exclusion. Cultured supernatants were centrifuged at 500 × g, 25°C for 5 minutes. 
Supernatants were kept for mMP isolation while cell pellets were further washed once 
with 1 mL FACS buffer before being centrifuged at 500 × g, 25°C for 5 minutes. Cell 
pellets were collected and used directly for flow cytometry and clot time analysis.  
 
Monocytic MP isolation was performed by subjecting culture supernatants to another 
centrifugation at 1,200 × g, for 5 minutes, at 25°C followed by ultracentrifugation at 
20,000 × g, for an hour, at 4°C. The pellets containing mMP were collected and used 
directly for flow cytometry and clot time analysis, and culture with HUVEC.  
 
 
2.5.3(b) Endothelial MP (eMP)  
Confluent HUVEC were seeded onto a treated 6-well plate at 1 × 105 cells/mL 
complete Endothelial Growth Medium 2. Cells were grown for 24 hours until they 
reach 70 - 80% confluence in a 37°C, 5% CO2/air atmosphere incubator. To mimic 
inflammatory condition, confluent endothelial monolayer was stimulated with 1 




from LPS-stimulated or unstimulated monocytes for 18 hours in a 37°C, 5% CO2/air 
atmosphere incubator (Wang et al., 2011). Following incubation, culture supernatants 
were collected into a new tube. Attached HUVEC were trypsinised and centrifuged at 
220 × g for 3 minutes at 25°C. Cell pellets were washed once with 1 mL FACS buffer 
before being centrifuged at 500 × g, 25°C for 5 minutes. Cell pellets were resuspended 
in FACS buffer for flow cytometry analysis.  
 
Cultured supernatants containing eMP were centrifuged at 500 × g, 25°C for 5 minutes. 
Then, supernatants were collected and subjected to another centrifugation at 1,200 × 
g, for 5 minutes, at 25°C followed by ultracentrifugation at 20,000 × g, for an hour, at 
4°C. The pellets were collected and resuspended in 1X Binding buffer for flow 
cytometry analysis.  
 
 
2.5.4 Endotoxin detection test  
Isolated mMP were assessed for the interference of endotoxin using a ToxinSensor 
Chromogenic Limulus Amebocyte Lysate Endotoxin Kit according to manufacturer’s 
instructions. Briefly, 100 µl of mMP were dispensed into endotoxin-free vials and 
mixed thoroughly for 30 seconds. Then, 100 µl of reconstituted Limulus Amebocyte 
Lysate (LAL) was added to each vial and mixed well by swirling gently followed by 
incubation at 37°C in water bath for 45 minutes. After incubation, 100 µl of 
reconstituted chromogenic substrate solution was added to each vials before being 
swirl gently. The solution were then incubated at 37°C in water bath for 6 minutes. 
Subsequently, 500 µl of reconstituted Color-stabilizer #1 (stop solution) was added to 




reconstituted Color-stabilizer #2. The solution was mixed before 500 µl of 
reconstituted color-stabilizer #1 was added to each vials. Lastly, the solution was 
mixed gently and the absorbance of each reaction was read at 545 nm using a 




2.5.5 Monocytic MP quantification by spectrophotometer 
Isolated mMP derived from monocytes were counted based on protein concentration 
using a NanoDrop ND-2000 spectrophotometer (Sahler et al., 2014). Two µL of mMP 
sample was loaded onto the lower pedestal of the spectophotometer and were measured 
at 280 nm.  
 
 
2.5.6 Monocytic MP quantification using BD TruCount Tubes 
BD TruCount tubes were added with 20 µL of anti-CD14 and anti-CD16 antibodies. 
Then, 50 µL of mMP samples were added and mixed by using a vortex. Samples were 
incubated for 15 minutes in the dark at room temperature. After incubation, 350 µL 
1X binding buffer were added and samples were mixed using a vortex. Samples were 
then incubated for another 15 minutes in the dark at room temperature before being 
analysed using a flow cytometer. Absolute count of mMP was quantified based on the 











2.5.7 Cell and MP staining for flow cytometry 
Following 18 hours culture, whole monocytes, CD14+ monocytes and CD16+ 
monocytes at 2 × 105 cells/mL were resuspended in 50 µL FACS buffer and 
subsequently incubated with 0.1 µg/mL of human phycoerythrin (PE)-conjugated anti-
human CD14, and allophycocyanin (APC)-conjugated anti-human CD16. To identify 
surface antigen expression on HUVEC, 1 × 106 cells/mL HUVEC were resuspended 
in 50 µL FACS buffer and directly stained with 0.1 µg/mL peridinin chlorophyll A 
protein (PerCP/Cy5.5)-conjugated anti-human CD31 and Annexin-V-fluorescein 
isothiocyanate (FITC). All cells were incubated for 20 minutes in the dark at 2 – 8°C. 
Labelled cells were centrifuged at 500 × g for 5 minutes at 25°C and pellets were 
resuspended in 400 µL FACS buffer followed by flow cytometry analysis. 
 
Following MP isolation, mMP and eMP pellets were resuspended in 100 µL 1X 
Binding buffer. Monocytic MP were subsequently incubated with Annexin-V-FITC, 
0.1 µg/mL PE-conjugated anti-human CD14, and APC-conjugated anti-human CD16. 
Meanwhile, eMP were incubated with Annexin-V-FITC and 0.1 µg/mL PerCP/Cy5.5-
conjugated anti-human CD31. All MP were incubated for 20 minutes in the dark at 
room temperature. Then, 1X binding buffer was added up to 400 µL before being 
analysed by flow cytometry.   
mMP absolute count =  X      N          X= Number of positive cell events 
       (mMP/ µL)             Y      V          Y= number of bead events 
              N= Number of beads per test (50600) 






MFI (fold change) = MFI sample / MFI control 
 
2.5.8 Data acquisition and flow cytometry analyses 
Stained samples were acquired using FACS Canto II flow cytometer for both cells and 
MP to determine surface antigen expressions. Appropriate flow cytometric colour 
compensation was performed using CompBeads. Cells were gated based on forward 
scatter (FSC) and size scatter (SSC) on linear scale. Approximately, 10,000 cell events 
were acquired at a medium flow rate. Monocytic MP and eMP were assessed based on 
logarithmic scale of FSC and SSC profiles. The lower minimum threshold was 
determined on FITC at 200 above the background noise. Monocytic MP and eMP were 
acquired at 50,000 events within the MP gate at a low flow rate.   
 
Flow cytometry data analyses were performed using FCS Express 5 software. The 
expression of surface antigen on MP was determined based on double positive staining 
for Annexin-V and appropriate antigens of interest. Meanwhile, the expression of 
surface antigens on monocyte subsets or HUVEC were determined based on the mean 
fluorescence intensity (MFI). The MFI of the sample was determined by fold change 










2.5.9 Prothrombin time (PT) assay  
Isolated monocytes and their mMP were resuspended in 50 µL complete AB medium. 
Samples were loaded into a cuvette and incubated with 50 µL pre-warmed normal 
pooled plasma for 180 seconds at 37°C. Then, 50 µL neoplastine was added to the 




2.5.10 General molecular methods 
2.5.10(a) Total RNA extraction  
The total RNA of human umbilical vein endothelial cells (HUVEC) was extracted 
using RNeasy Mini Kit according to the manufacturer’s instructions. Following 
HUVEC isolation, 600 µL of Buffer RLT was added to the cell before being mixed 
using a vortex for one minute. Then, 600 µL of 70% ethanol was added to the lysate 
and mixed by pipetting. The sample was transferred to an RNeasy Mini spin column 
in a 2 ml collection tube. The sample was centrifuged at 9,280 × g for 15 seconds. The 
flow through was discarded followed by the addition of 700 µL of Buffer RW1 before 
being centrifuged at 9,280 × g for another 15 seconds. The steps were repeated twice 
with the addition of 500 µL of Buffer RPE and the second centrifugation was two 
minutes at the same speed. Then, the mixture was further centrifuged at maximum 
speed (31,514 × g) for one minute. The RNeasy spin column was placed in a new 1.5 
mL collection tube and 40 µL of RNase-free water was directly added to the spin 




elute the RNA. Isolated total RNA was collected and used immediately for real-time 
PCR analysis.  
 
 
2.5.10(b) Determination of RNA concentration and purity  
The total RNA concentration was quantified using a NanoDrop ND-2000 
spectrophotometer. Two µL of RNA was loaded onto the lower pedestal of the 
spectrophotometer and the sample was measured at 450 nm. The concentration of 
RNA was determined by OD280 absorbance and presented as µg/mL. The RNA purity 
was then assessed based on the ratio of A260nm/A280nm. 
 
 
2.5.10(c) RNA integrity test 
The extracted total RNA of HUVEC was assessed for RNA integrity by gel 
electrophoresis. Agarose gel was prepared by mixing 0.8% agarose powder in 1X Tris-
Acetate-EDTA (TAE) buffer. The mixture was then loaded into the gel cassette and 
allowed to solidify for 30 minutes. Then, solidified agarose gel was transferred into 
the casting tray and TAE buffer was loaded into the casting tray until the agarose gel 
was covered. The total RNA samples were mixed with 6X RNA loading dye in a ratio 
of 1:5, whereas the RiboRuler High Range RNA ladder was mixed with loading dye 
in a ratio of 1:1 before being loaded into the gel. Gel electrophoresis was conducted at 
70 V for 50 minutes. Then, denaturing agarose gel was stained with ethidium bromide 
(EtBr) for 5 minutes followed by observation of total RNA under ultraviolet (UV) light 




2.5.10(d) Dilution of GAPDH, intercellular adhesion molecule 1 (ICAM-1), and 
vascular cell adhesion molecule 1 primers (VCAM-1) 
Lyphophilised GAPDH, intercellular adhesion molecule 1 (ICAM-1), and vascular 
cell adhesion molecule 1 (VCAM-1) primers were dissolved in appropriate volume of 
RNase-Free water as recommended by the manufacturer to make up 100 µM primer 
stocks. All primers were further diluted in RNase-Free water to the final concentration 
of 10 µM. Reconstituted stock solutions were dispensed at 100 µL into 
microcentrifuge tubes and stored at -20°C until used. 
 
 
2.5.10(e) Determination of amplification efficiency 
The amplification efficiency (E) of real-time PCR was assessed using a serial dilution 
method. The RNA template was diluted at 5 points of 1:2 serial dilution factors which 
were 10, 5, 2.5, 1.25 and 0.625 ng of RNA prior to real-time PCR assay. Subsequently, 
standard curves were generated based on the Ct value and RNA concentrations. The 
linearity of the standard curves was further assessed based on Pearson’s coefficient (r) 
test. The amplification efficiency of real-time PCR assay was determined based on the 




                       E (%) =    -1 
        10slope – 1 
 






2.5.11 Detection of ICAM-1 and VCAM-1 expression 
Prior to real-time PCR assay, samples were prepared using LUNA® Universal One-
Step RT-qPCR Kit as the manufacturer’s instructions (Table 2.6). Briefly, mastermix 
solution was prepared by mixing the reagents to a final concentration of 1X Luna 
Universal One-Step reaction Mix, 1X Luna WartStart RT Enzyme Mix, 0.4 µM 
forward and reverse primers and 2.7 µL of Nuclease-free water. Subsequently, 9µL of 
the mastermix solution was dispensed into the 0.2 mL real-time PCR microcentrifuge 
tubes. The RNA template with a final concentration of 0.1µg/mL was further added 
into the mastermix solution to the final volume of 10 µL followed by real-time PCR 
assay immediately.  
 
Detection of adhesion molecules ICAM-1 and VCAM-1 by real-time PCR was 
performed using a SYBR Green approach. Primer sequences were adapted from 
previous studies (Baek et al., 2018; Chu et al., 2017) and synthesised by Apical 
Scientific (Table 2.7). GAPDH was used as a reference gene and non-template sample 
was used as a negative control. The thermal cycling conditions were listed as in Table 
2.8. Dissociation stage was performed based on the recommendation by the real-time 










Table 2.6: Preparation of samples for real-time PCR assay. 
Components 10 µl reaction Final concentration 
Luna Universal One-Step 
Reaction Mix (2X) 
5.0 µL 1X 
Luna WarmStart RT 
Enzyme Mix (20X) 
0.5 µL 1X 
Forward primer (10 µM) 0.4 µL 0.4 µM 
Reverse primer (10 µM) 0.4 µL 0.4 µM 
Template RNA 1.0 µL ≤ 1 µg (total RNA) 
Nuclease-free water 
2.7 µL - 
 
 
Table 2.7: The primer sequence for real-time PCR 




GGC CGG CCA GCT TAT 
ACA C 





TCA GAT TGG AGA CTC 
AGT CAT GT 





CCT GCA CCA CCA ACT 
GCT TA 
GGC CAT CCA CAG TCT 
TCT GAG 









Table 2.8: The thermal cycling condition for ICAM-1 and VCAM-1 expression using 
real-time PCR 
Cycle steps Temperature Time Cycles Stage 
Reverse 
transcription 
55°C 10 minutes 1 1 
Initial 
denaturation 
95°C 1 minutes 1 2 
Denaturation 95°C 10 seconds 40 3 
Extension 60°C 60 seconds 1 3 
Dissociation 
stage 




2.5.12 Data acquisition by real-time PCR 
Data acquisition of real-time PCR was performed using Applied Biosystem 7500 real-
time PCR machine and the cycle threshold were obtained by ABi 7500 real-time PCR 
software. 
 
The relative expression level of ICAM-1 and VCAM-1 was further calculated in a fold 
change over control by using double delta Ct analysis (2–ΔΔCt ) method (Rao et al., 
2013) as the following formula: 
 
   TE = Tested experimental gene 
   HE = Housekeeping gene experimental 
   TC = Tested control gene 
   HC = Housekeeping gene control 
 
   Step 1: Calculate ΔCTE and ΔCTC   
    ΔCTE = TE – HE   
    ΔCTC = TC – HC  
   Step 2: Calculate ΔΔCt 
    ΔΔCt = ΔCTE – ΔCTC 






2.5.13 Statistical analyses 
Statistical analyses were performed using paired Student’s t-test by Graphpad Prism 
7.0 software for all experimental data. Data were presented as means ± standard error 
of mean (SEM). Values of P<0.05 (*), P<0.01 (**) and P<0.001 (***) were 
considered statistically significant. Experiment was repeated for at least three 
















CHAPTER 3  
RESULTS 
 
3.1 Identification of monocyte populations in peripheral blood 
mononuclear cells (PBMC) 
Monocyte populations were identified on PBMC by the expression of CD14 and 
CD16. PBMC populations were detected based on SSC/FSC profiles by flow 
cytometry (Figure 3.1A) before being further gated based on the expression of CD14 
and CD16. The percentage of monocytes that express CD14+ and CD16+ was 41.10% 
and 19.79% respectively (Figure 3.1B).  
 
 
Figure 3.1: Identification of monocyte populations in PBMC. PBMC were stained 
with anti-CD14 and anti-CD16 followed by flow cytometry analyses. A) Dot plot 
shows live monocytes in PBMC based on SSC/FSC profiles. B) Dot plot shows the 
expression of CD14 and CD16 on gated monocytes. Data are representative from four 






3.2 Cell surface phenotypes of monocytes 
3.2.1 Purity of whole monocytes 
Whole monocytes were isolated from PBMC and were collected from the negative 
fraction using Pan Monocyte Isolation Kit as described previously in Section 2.5.3(b). 
Following isolation, whole monocytes were identified based on SSC/FSC profiles 
(Figure 3.2A) before being further gated based on CD14 and CD16 expressions 
(Figure 3.2B). The purity of whole monocytes, CD14+ monocytes (Figure 3.2C), and 












                      
 
Figure 3.2: Purity of whole monocytes, CD14+ monocytes, and CD16+ monocytes 
following immunomagnetic isolation. Whole monocytes, CD14+ monocytes, and 
CD16+ monocytes were stained with anti-CD14 and anti-CD16 prior to flow cytometry 
analyses. A) Purified whole monocytes were gated on SSC/FSC profile and further 
gated on B) CD14/CD16. Dot plots show the positive population of C) CD14+ 
monocytes and D) CD16+ monocytes were assessed based on CD14 and CD16 












3.2.2 Assessment of CD14 and CD16 expressions on whole monocytes, CD14+ 
monocytes, and CD16+ monocytes 
The expression of CD14 and CD16 on whole monocytes, CD14+ monocytes, and 
CD16+ monocytes was assessed by flow cytometry following 18 hours culture in the 
presence or absence of LPS. The intensity of CD14 and CD16 expressions on all 
monocyte subtypes were determined based on the mean fluorescence intensity (MFI). 
 
The expression of CD14 and CD16 on whole monocytes were 34130.70 and 745.92 at 
0 hour respectively (Figure 3.3A). Following 18 hours culture, the expression of CD14 
on unstimulated whole monocytes was 27407.70, which was higher compared to their 
LPS-stimulated counterparts which was 19024.20. The expression of CD16 on 
unstimulated and LPS-stimulated whole monocytes was albeit low, which was 
approximately 440.36 and 368.42 respectively.  
 
On CD14+ monocytes, the intensity of CD14 and CD16 expressions at 0 hour were 
34570.13 and 687.36 respectively (Figure 3.3B). In the presence of LPS, the intensity 
of CD14 expression on CD14+ monocytes was 16852.05, which was lower compared 
to 21199.73 on unstimulated CD14+ monocytes. Similarly, the expression of CD16 on 
CD14+ monocytes was low where the expression intensity was 244.80 on unstimulated 
CD14+ monocytes and 194.88 on LPS-stimulated CD14+ monocytes. 
 
Meanwhile, the expression of CD14 and CD16 on CD16+ monocytes at 0 hour were 
646.68 and 2693.39 respectively (Figure 3.3C).  The expression of CD14 on CD16+ 
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Figure 3.3: The expression of CD14 and CD16 on monocyte subsets. Whole 
monocytes, CD14+ monocytes, and CD16+ monocytes were labelled with anti-CD14 
and anti-CD16 antibodies prior to flow cytometry analysis. Histograms show the 
expression of CD14 and CD16 on unstimulated (black line) and stimulated (grey-
filled) A) whole monocytes, B) CD14+ monocytes and C) CD16+ monocytes at 0 and 
18 hours of  culture in the presence or absence of LPS. Isotype controls (dotted line) 
were used as negative controls. D) Fold change in mean fluorescence intensity (MFI) 
of CD14 and CD16 expressions on monocyte subsets over control of all monocyte 
subsets following 18 hours culture. Data shown are representative from four 
independent experiments. Error bars represent mean ± standard error of the mean 




unstimulated CD16+ monocytes was 320.96, while on LPS-stimulated CD16+ 
monocytes was 306. In contrast, the MFI intensity of CD16 expression on unstimulated 
CD16+ monocytes was 714.29 compared to LPS-stimulated CD16+ monocytes, which 
was 841.93.   
 
The changes in MFI of CD14 and CD16 expressions on all unstimulated and LPS-
stimulated monocyte subsets following 18 hours culture were statistically analysed 
(n=4) (Figure 3.3D–F). The changes in MFI were calculated as fold change over 
control, which was defined by MFI of sample divided by the MFI of isotype control. 
The expression of CD14 and CD16 on all monocyte subtypes was reduced following 
LPS stimulation with the exception of CD16 expression on CD16+ monocytes. 
 
The expression of CD14 on unstimulated whole monocytes was 49.56 fold higher than 
isotype control. In the presence of LPS, CD14 expression on whole monocytes 
decreased to 32.72 fold (p=0.008) than on unstimulated monocytes. A similar 
expression pattern was observed for CD16 expression on whole monocytes. The 
expression of CD16 on unstimulated whole monocytes was 2.45 fold and significantly 
decreased to 1.75 fold (p=0.03) on LPS-stimulated whole monocytes. 
 
A significant decrease of CD14 expression was observed on LPS-stimulated CD14+ 
monocytes, which was 37.73 fold compared to 51.17 fold (p=0.026) on unstimulated 
CD14+ monocytes (Figure 3.3.E). Despite low MFI, CD16 expression on LPS-
stimulated CD14+ monocytes was 1.56 fold which was significantly lower compared 




In the presence of LPS, CD14 expression on CD16+ monocytes was 1.32 fold higher 
than isotype control and decreased to 1.26 fold on LPS-stimulated CD16+ monocytes 
(Figure 3.3F). In contrast, CD16 expression on unstimulated CD16+ monocytes was 
3.41 fold and increased to 3.82 fold on LPS-stimulated CD16+ monocytes, although 
not significant.  
 
 
3.3 Quantification of monocytic microparticles (mMP)  
Monocytic MP derived from the whole monocytes, CD14+ monocytes, and CD16+ 
monocytes were quantified by using TruCount beads to obtain the absolute amount of 
mMP (mMP/µL) released in culture supernatants. The absolute amount of mMP was 
defined by (events of mMP/beads events) × (total number of beads/total volume). Bead 
events were obtained from Trucount beads region gated on SSC/FSC profiles (Figure 
3.4A), while the number of Annexin-V+/antigen+ mMP events were obtained from the 
region gated on Annexin-V+/CD14+ or Annexin-V+/CD16+. 
 
The absolute number of Annexin-V+/CD14+ mMP derived from unstimulated whole 
monocytes was 288.1 ± 114.1 mMP/µL and significantly increased on LPS-stimulated 
whole monocytes, which was 564.1 ± 100.4 mMP/µL (p=0.014) (Figure 3.4B). 
Likewise, the absolute count of Annexin-V+/CD16+ mMP from unstimulated whole 
monocytes was 258.1 ± 27.78 mMP/µL, which was significantly lower compared to 






      
                                           
Figure 3.4: Quantification of mMP derived from monocyte subsets by TruCount 
beads. A) Monocytic MP population and TruCount beads were assessed on SSC/FSC 
profiles. Unstained and stained mMP were further gated on Annexin-V+/CD14+ and 
Annexin-V+/CD16+ populations. Absolute number of mMP derived from B) whole 
monocytes, C) CD14+ monocytes, and D) CD16+ monocytes were quantified in the 
presence or absence of LPS. Data shown are representative from three independent 





In the absence of LPS, the absolute count of Annexin-V+/CD14+ mMP derived from 
unstimulated CD14+ monocytes was 223.6 ± 23.87 mMP/µL and increased to 581.4 ± 
172.3 mMP/µL following LPS stimulation, although not significant (Figure 3.4C). 
Meanwhile, the absolute number of LPS-stimulated CD14+ monocyte-derived mMP 
expressing Annexin-V+/CD16+ increased to 608.2 ± 217.8 mMP/µL compared to those 
derived from unstimulated CD14+ monocytes which was 294.5 ± 53.76 mMP/µL.  
 
Meanwhile, the number of mMP expressing Annexin-V+/CD14+ derived from CD16+ 
monocytes decreased in the presence of LPS. The number of Annexin-V+/CD14+ mMP 
derived from unstimulated CD16+ monocytes was 313.1 ± 77.31 mMP/µl compared 
to their LPS-stimulated counterparts which was 584.6 ± 46 mMP/µL (Figure 3.4D). 
Similarly, the count of Annexin-V+/CD16+ derived from unstimulated CD16+ 
monocytes was 409.5 ± 181.2 mMP/µL and the expression of Annexin-V+/CD16+ on 











3.4 Assessment of CD14 and CD16 expressions on mMP derived from 
whole monocytes, CD14+ monocytes, and CD16+ monocytes 
The expression of CD14 and CD16 in combination with Annexin-V was assessed on 
mMP derived from the whole monocytes, CD14+ monocytes, and CD16+ monocytes. 
Monocytic MP were isolated from culture supernatants as described in Section 
2.5.4(a). The detection of endotoxin level in mMP derived from all monocyte subsets 
was initially performed using ToxinSensorTM Chromogenic Limulus Amebocyte 
Lysate (LAL) Endotoxin Assay Kit. All mMP cultures in this study were free from 
endotoxin contamination as determined by the endotoxin detection assay (~0.7 
EU/mL). By using forward and side scatter on logarithmic scale of a flow cytometer, 
mMP were identified based on the expression of PS indicated by Annexin-V and CD14 
or CD16 (Figure 3.5). 
 
CD14 and CD16 in combination with Annexin-V were expressed on all mMP derived 
from unstimulated and LPS-stimulated whole monocytes, CD14+ monocytes, and 
CD16+ monocytes at different intensities. The expression of these antigens were higher 
on mMP derived from stimulated whole monocytes, CD14+ monocytes, and CD16+ 
monocytes compared to those from unstimulated mMP (Figure 3.4A–F).  
 
Monocytic MP derived from unstimulated whole monocytes express 4.03% Annexin-
V+/CD14+ and increased to 7.45% following LPS stimulation (Figure 3.5A). Likewise, 
the expression of Annexin-V+/CD14+ on mMP derived from unstimulated CD14+ 
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Figure 3.5: The expression of CD14 and CD16 on mMP derived from whole 
monocytes, CD14+ monocytes, and CD16+ monocytes. Monocytic MP derived from 
all monocyte subtypes were stained with Annexin-V in combination with anti- CD14 
or anti-CD16. A–C) Dot plots show mMP population derived from unstimulated and 
LPS-stimulated cells gated on Annexin-V+/CD14+ and D–F) Annexin-V+/CD16+ 
population. Isotype control was used as a negative control. Percentage of double 
positive mMP population derived from G) whole monocytes, H) CD14+ monocytes, 
and I) CD16+ monocytes were calculated. Data shown are representative from three 
independent experiments. Error bars represent mean ± standard error of the mean 




monocytes was 5.78% (Figure 3.5B). Meanwhile, the expression of Annexin- 
V+/CD14+ on mMP derived from unstimulated and LPS-stimulated CD16+ monocytes 
was relatively low, which was only 1.55% and 3.79% respectively (Figure 3.5C).  
 
Meanwhile, the expression of Annexin-V+/CD16+ was 3.56% on mMP derived from 
unstimulated whole monocytes (Figure 3.5D). This expression was elevated to 7.08% 
on mMP derived from LPS-stimulated whole monocytes. Similarly, the expression of 
Annexin-V+/CD16+ on mMP derived from unstimulated CD14+ monocytes was 2.99% 
and increased to 5.74% on those derived from LPS-stimulated CD14+ monocytes 
(Figure 3.5E). On mMP derived from unstimulated CD16+ monocytes, the expression 
of Annexin-V+/CD16+ was only 1.43% (Figure 3.5F). However, the expression of 
Annexin-V+/CD16+ was higher on LPS-stimulated CD16+ monocyte-derived mMP 
which was 3.65%. 
 
Overall, the expression of Annexin-V in combination with CD14 or CD16 on mMP 
from three independent experiments were increased on LPS-stimulated monocyte-
derived mMP compared to their unstimulated counterparts (Figure 3.5G–I). The 
percentage of Annexin-V+/CD14+ on LPS-stimulated whole monocyte-derived mMP 
was significantly higher by 7.01 ± 1.19% compared to on mMP derived from 
unstimulated whole monocytes which was 3.44 ± 1.2% (p=0.006) (Figure 3.5G). The 
expression of Annexin-V+/CD16+ on LPS-stimulated whole monocyte-derived mMP 
was 4.747 ± 1.19% compared to on whole monocyte-derived mMP in the absence of 






Similarly, a significant increase of Annexin-V+/CD14+ and Annexin-V+/CD16+ 
expressions was observed for CD14+ monocytes-derived mMP (Figure 3.5H). The 
expression of Annexin-V+/CD14+ on LPS-stimulated CD14+ monocyte-derived mMP 
was 6.14 ± 0.29% compared to their unstimulated counterparts, which was 2.98 ± 
0.31% (p=0.032). The percentage of Annexin-V+/CD16+ expression on unstimulated 
CD14+ monocyte-derived mMP was 0.27 ± 0.72%. In the presence of LPS, these 
antigen expression on CD14+ monocyte-derived mMP was significantly increased to 
6.48 ± 0.49% (p=0.033). 
 
The percentage of Annexin-V+/CD14+ expression was significantly increased from  
0.20 ± 0.38% on mMP derived from unstimulated CD16+ monocytes to 4.02 ± 0.20% 
(p=0.039) on those from LPS-stimulated CD16+ monocytes (Figure 3.5I). A similar 
expression pattern was observed for Annexin-V+/CD16+ on CD16+ monocytes. 
Approximately 4.11 ± 0.3% of Annexin-V+/CD16+ was expressed on LPS-stimulated 
CD16+ monocyte-derived mMP compared to 1.69 ±0.51% on mMP derived from 









3.5 Assessment of mMP role in coagulation 
3.5.1 CD142 expression on monocyte subsets and their derived mMP 
The expression of CD142 or tissue factor (TF) was assessed on LPS-stimulated whole 
monocytes (Figure 3.6A), CD14+ monocytes (Figure 3.6B), and CD16+ monocytes 
(Figure 3.6C) as well as their derived mMP. The MFI of CD142 expression was 
calculated as fold change over control.   
The intensity of CD142 expression on unstimulated whole monocytes was 1.951 fold 
compared to isotype control and significantly increased to 2.77 fold (p=0.005) upon 
LPS stimulation (Figure 3.6D). Likewise, CD142 expression was higher on LPS-
stimulated CD14+ monocytes which was 3.24 fold compared to 2.71 fold on 
unstimulated CD14+ monocytes although not significant. Meanwhile, the expression 
intensity of CD142 was significantly increased from 1.14 fold on unstimulated CD16+ 
monocytes to 1.52 fold (p=0.018) on LPS-stimulated CD16+ monocytes.   
 
On the other hand, the percentage of Annexin-V+/CD142+ expressed on mMP derived 
from unstimulated whole monocytes was 7.56 ± 1.09% (Figure 3.6E). The percentage 
of Annexin-V+/CD142+ on whole monocytes-derived mMP was significantly 
increased to 11.16 ± 0.84% (p=0.015) in the presence of LPS. The percentage of 
monocytic MP derived from unstimulated CD14+ monocytes which expressed 
Annexin-V+/CD142+ was 1.43 ± 0.1% and increased to 3.01 ± 0.46% on mMP derived 
from stimulated CD14+ monocytes, however not significant. Likewise, Annexin-
V+/CD142+ expressed on mMP derived from unstimulated CD16+ monocytes was 0.27 
± 0.7%, which was lower compared to 3.32 ± 0.19% on LPS-stimulated CD16+ 






Figure 3.6: The expression of CD142 on monocyte subsets and their derived 
mMP. Histogram show the expression of CD142 on A) whole monocytes, B) CD14+ 
monocytes, and C) CD16+ monocytes. D) Bar chart shows the fold change of CD142 
expression on whole monocytes, CD14+ monocytes, and CD16+ monocytes. E) Bar 
chart shows the percentage of CD142 expression in combination with Annexin-V on 
mMP derived from whole monocytes, CD14+ monocytes, and CD16+ monocytes. Data 
shown are representative from three independent experiments. Error bars represent 







3.5.2 Analysis of prothrombin time (PT) in the presence of mMP 
The increased expression of CD142 on mMP derived from whole monocytes led us to 
assess clotting time in the presence of mMP by measuring prothrombin time. The 
clotting time was first assessed on whole monocytes and PBMC as a control. Normal 
pooled plasma was used as an experimental control to determine the normal range of 
clotting time in a healthy physiological state.  
 
This study has shown that plasma clotting time were unaffected by the addition of both 
unstimulated and stimulated monocytes regardless the concentration of the cells used 
(Figure 3.7). The plasma clotting time for unstimulated monocytes at 1 × 106 cells/mL 
was 12.70 ± 0.21 seconds. The time taken for clot formation was slightly reduced after 
the addition of LPS-stimulated monocytes at 1 × 106 cells/mL, which was 12.97 ± 
0.09. Similarly, the plasma clotting time for unstimulated monocytes at 5 × 106 
cells/mL was 16.9 ± 3.95 seconds and slightly reduced to 16.2 ± 3.6 seconds in the 
presence of a similar cell concentration of LPS-stimulated monocytes. 
 
In contrast, plasma clotting time was reduced in the presence of mMP derived from 
LPS-stimulated monocytes. A significant reduction in time taken for clot formation 
was observed after a higher concentration of mMP derived from stimulated monocytes 
was added. Prothrombin time of mMP derived from unstimulated monocytes at 1 × 
106 cells/mL was 18.47 ± 5.72 seconds and decreased to 17.73 ± 5.19 seconds in the 
presence mMP derived from stimulated monocytes. The addition of higher mMP 
concentration derived from stimulated monocytes at 5 × 106 cells/mL resulted in a 
significant reduction of clotting time, which was 12.43 ± 0.89 seconds compared to 






Figure 3.7: Plasma clotting time by monocytes and their derived mMP. 
Prothrombin time (PT) assay was performed using semi-automated Start 4 
coagulometer. Bar charts represent the plasma clotting time taken for monocytes and 
their derived mMP after incubation with normal pooled plasma for 180 seconds 
followed by the addition of neoplastin. Normal pooled plasma was used as a control. 
Results are from three independent experiments. Error bars represent mean ± standard 



















3.6 Assessment of endothelial cell activation in the presence of mMP 
3.6.1 Expression of endothelial cell markers following culture with mMP 
The potential role of mMP in altering endothelial cell phenotype was examined. The 
expression of CD31 on endothelial cells was first identified by flow cytometry. 
Confluent monolayers of HUVEC were successfully cultured in the presence or 
absence of mMP. HUVEC expressed CD31 at various intensities depending on the 
type of stimulation (Figure 3.8A). The expression of CD31 on HUVEC without 
stimulation was 19.28 fold higher than isotype control and significantly increased to 
39.83 fold (p=0.005) in the presence of mMP derived from unstimulated monocytes. 
In the presence of mMP derived from LPS-stimulated monocytes, CD31 expression 
on HUVEC was 46.15 fold, which was significantly higher compared to 36 fold 
(p=0.033) when modulated by LPS alone.  
 
Meanwhile, the level of ICAM-1 and VCAM-1 expression was conducted by serum-
starving HUVEC followed by incubation with or without mMP. The integrity of 
HUVEC total RNA was first assessed using gel electrophoresis, which was highly 
integrated (Appendix A). The expression level of ICAM-1 and VCAM-1 by 
endothelial cells were analysed by real-time PCR. GAPDH was chosen as a reference 
gene while unstimulated HUVEC was used as a negative control. High linearity for 
slope of standard curve was obtained for GAPDH, ICAM-1, and VCAM-1 (Appendix 
B). Meanwhile, the amplification efficiency of real-time PCR assay was 105.12% for 







Figure 3.8: The expression of endothelial cell markers on HUVEC in the presence 
of mMP. HUVEC were stimulated with LPS, unstimulated monocyte-derived mMP, 
or LPS-stimulated monocyte-derived mMP. The expression of A) CD31, B) ICAM-1, 
and C) VCAM-1 were calculated in a relative fold change. Unstimulated HUVEC were 
used as an experimental negative control and GAPDH was used as a reference gene. 
Results are representative from three independent experiments. Error bars represent 




Under serum-free condition, mMP were able to govern the expression of adhesion 
molecules on HUVEC. Monocytic MP from both unstimulated and LPS-stimulated 
monocytes induced the expression of ICAM-1 (Figure 3.8B) and VCAM-1 (Figure 
3.8C). In the presence of unstimulated monocyte-derived mMP, the expression of 
ICAM-1 on HUVEC was increased 19.22 fold compared to unstimulated HUVEC. 
Meanwhile, the expression of ICAM-1 on HUVEC in the presence of LPS-stimulated 
monocyte-derived mMP was increased 24.42 fold compared to HUVEC stimulated 
with LPS alone which was 4.58 fold. 
 
Similarly, the expression of VCAM-1 was significantly higher on HUVEC stimulated 
with unstimulated monocyte-derived mMP, which was 59.30 fold (p=0.002) compared 
to unstimulated HUVEC. In the presence of mMP derived from LPS-stimulated 
monocytes, the expression of VCAM-1 was 86.49 fold, which was significantly higher 















3.6.2 CD31 expression on endothelial microparticles (eMP) in the presence 
of mMP  
After demonstrating the capability of mMP from monocytes in enhancing the 
expression of CD31 and adhesion molecules by HUVEC, we further assessed the eMP 
production upon culture with mMP. Endothelial MP population was identified based 
on the SSC/FSC profiles of a flow cytometer, followed by gating on Annexin-
V+/CD31+ population. Culture supernatants from unstimulated HUVEC was analysed 
for the presence of eMP to determine the baseline production of eMP.  
 
In the absence of LPS, the percentage of Annexin-V+/CD31+ on eMP was 15.23% 
(Figure 3.9A). The percentage of these antigens on eMP was increased to 24.01% 
following LPS stimulation (Figure 3.9B). In the presence of mMP from unstimulated 
whole monocytes, the percentage of Annexin-V+/CD31+ expression on eMP was 
17.96% (Figure 3.9C), which was lower compared to 30.94% with the presence of 






Figure 3.9: Analysis of CD31 expression on endothelial microparticles (eMP). 
Microparticles derived from endothelial cells were identified as Annexin-V+/CD31+ 
population on CD31/Annexin-V profile. Dot plots show the gated eMP population 
derived from A) unstimulated HUVEC, B) LPS-stimulated HUVEC, C) HUVEC 
stimulated with mMP from unstimulated monocytes, and D) HUVEC stimulated with 
mMP derived from LPS-stimulated monocytes. Results are representative from three 














CHAPTER 4  
DISCUSSION 
 
Microparticles (MP) have gained interest due to their important role in various 
biological activities particularly in inflammation (Batool, 2013), thrombosis 
(Mooberry and Key, 2016), and endothelial dysfunction (Helbing et al., 2014). 
However, phenotypic characteristics and functional roles of MP derived from human 
blood monocytes remain unknown. Most in vitro studies on mMP were conducted by 
using cell lines or without distinguishing the blood monocyte subsets. Thus, this study 
intended to investigate the phenotypic profiles of mMP derived from different blood 
monocyte subsets such as whole monocytes, CD14+ monocytes, and CD16+ 
monocytes as well as their potential role in coagulation and endothelial cell functions.  
 
 
4.1 Expression of CD14 and CD16 on monocyte subsets  
Cell surface expression of whole monocytes, CD14+ monocytes and CD16+ monocytes 
as well as their derived mMP was examined. There are several types of stimuli used to 
generate mMP in vitro such as LPS, calcium ionophore, histamine (Cerri et al., 2006), 
and P-selectin–Ig chimera (Bernimoulin et al., 2009). Lipopolysaccharides (LPS) have 
been extensively used for immune cell activation due to its high binding capacity to 
CD14, a co-receptor for LPS. Additionally, LPS is able to elicit strong immune 
response in humans and activate immune cells via TLR 4 (Soop et al., 2013). The 
mechanism of TLR 4 activation by LPS involves the binding of LPS with serum LPS-
binding protein (LBP), in which LBP facilitates in transferring LPS molecule to CD14 




complex is essential to initiate cell activation efficiently through TLR 4 and MD-2 
molecule (Latz et al., 2002). MD-2 molecule is a protein that associates with TLR 4 
on the cell surface, forming a receptor complex for LPS recognition (Ohnishi et al., 
2003). TLR 4/MD-2 complex is a potent receptor for LPS recognition and evokes 
multimolecular complex on the plasma membrane (Borzęcka et al., 2013). Therefore, 
LPS was used in this study to induce mMP production by monocyte subsets. 
Optimisation of LPS concentration was initially performed to determine the optimum 
working concentration for mMP generation. The working concentration of 1 µg/mL 
LPS was chosen as it enhanced the release of mMP without compromising cell 
viability (Appendix C). 
 
The permeability of cell membrane is a vital indicator for cell function in in vitro 
studies (Aysun et al., 2016). A routine cell viability measurement after cell isolation 
and culture is critical to ensure the quality and reliability of cells (Mallone et al., 2011). 
In this study, cell viability assessment was performed using Trypan blue exclusion for 
all cell types to ensure that mMP were primarily released following LPS stimulation 
and not due to cell death. Only cells with 95% viability or higher were used for mMP 
assessment by flow cytometry as recommended previously (Bernimoulin et al., 2009). 
Apart from that, the contamination of endotoxin in mMP preparation and culture may 
severely affect the reliability of the experimental data. Endotoxin contamination may 
arise during cell culture preparations including from media, sera, consumables, and 
growth additives (Magalhães et al., 2007). In this study, no endotoxin contamination 
was detected in mMP.  
Upon cell activation by LPS, mMP were released into culture supernatants. Numerous 




precipitation, density gradient, and filtration. However, the choice of mMP separation 
method as well as the purity of mMP is crucial as contaminants may attribute to 
alteration of mMP function (Théry et al., 2018). Among all, the differential 
ultracentrifugation technique is widely used to isolate mMP (Gardiner et al., 2016). 
This method is able to isolate mMP with high recovery rate (Mateescu et al., 2017). In 
this study, culture supernatants were subjected to two-steps centrifugation followed by 
ultracentrifugation to isolate mMP as recommended previously (Crompot et al., 2015). 
Culture supernatants were first centrifuged at 500 × g to facilitate the separation and 
removal of cells from mMP in the supernatants. It has been reported that an initial 
centrifugation with lower speed between 300 and 500 × g for 5 to 20 minutes is a 
crucial step in obtaining cell-free supernatants (Orozco and Lewis, 2010). The second 
centrifugation at 1,200 × g was performed to remove remaining cells or debris in the 
supernatants (Coumans et al., 2017b), thus assisting in successful separation of true 
events from background noise during flow cytometry analysis (Dey-Hazra et al., 
2010). Low centrifugation speed may result in incomplete removal of cells and 
subsequently leads to flow cytometry analysis disturbances due to debris and unwanted 
cellular events (Dey-Hazra et al., 2010). Supernatants containing mMP were further 
ultracentrifuged at 20,000 × g as higher speed centrifugation is able to avoid exosome 
contamination during mMP isolation since mMP are pelleted and exosomes remain in 
the supernatant (Menck et al., 2017).  
 
It should be considered that some mMP might be lost during centrifugation. Therefore, 
mMP was isolated at 4°C to ensure their stability since ultracentrifugation may 
produce heat which leads to mMP degradation (Dey-Hazra et al., 2010). Additionally, 




2012) as delay in isolation may result in mMP loss and changes in mMP characteristics 
as well as their morphology (Dey-Hazra et al., 2010; Poncelet et al., 2015).  
 
In this study, flow cytometry was used to assess surface antigen expression by mMP 
(Crompot et al., 2015). During flow cytometry analysis, mMP was gated based on the 
positive expression for selected markers in combination with Annexin-V. A defined 
size beads have been previously used to facilitate detection of mMP on flow cytometry 
(Rousseau et al., 2015). In this study, particle-size beads were not used since they may 
generate non-specific staining; in addition, the refractive index of particle-size beads 
and mMP are different (van der Pol et al., 2012). This may result in underestimation 
of the size of mMP and therefore contribute to false-positive results (Crompot et al., 
2015).  
 
Nevertheless, the limitation of mMP analysis using conventional flow cytometry has 
been persistently debated due to the smaller size of mMP compared to normal blood 
cells. Firstly, the minimal detection limit for light scattering of conventional flow 
cytometry is approximately 0.5 µm (van der Pol et al., 2010). However, only a small 
fraction of mMP with size 0.5 µm or larger can be efficiently resolved, which affects 
the analysis of smaller mMP population (Chandler et al., 2011). The flow cytometric 
threshold has been recommended to be extended down to as low as possible to 
determine mMP of 1 µm or less in diameter (Menck et al., 2017). Therefore, in this 
study, a lower minimum threshold at 200 was defined on FITC parameter just above 
the background noise, which theoretically the defined threshold discriminates the high 
background noise and excludes debris (Inglis et al., 2015). Secondly, overlapping 




mMP detection, which is below 0.2–0.3 µm by conventional flow cytometer 
(Pospichalova et al., 2015). A significant amount of background noise due to cell 
debris and precipitates is generated from unfiltered buffers, leading to false-positive 
microparticle analysis (Dey-Hazra et al., 2010; Nielsen et al., 2014). As it is crucial to 
eliminate contaminating particles in buffers or fluidic system prior to flow cytometry 
analysis, therefore, all buffer used for flow cytometry analysis were initially filtered 
using 0.2 µm filter in this study as previously recommended (Rousseau et al., 2015). 
Additionally, mMP were assessed based on forward scatter (FSC) and side scatter 
(SSC) on the logarithmic scale in this study. As mMP may generate dim signals close 
to the background noise, the use of logarithmic scale assists in visualising small 
particles and separation of actual events from scatter noise on the dot plots (Nielsen et 
al., 2014). Thirdly, occurrences of swarm or coincidence detection of mMP due to 
small size could lead to misinterpretation of results (Rousseau et al., 2015). Swarm or 
coincidence detection may occur when multiple smaller mMP are detected and 
therefore are considered as a large single mMP as the fluorescence merges into a single 
electronic event (Chandler, 2016). To best overcome this limitation, accurate 
discrimination between coincident event and fluorescent event as well as good 
resolution of mMP may be achieved with low acquisition rate (Nolan and Jones, 2017; 
Pospichalova et al., 2015). Therefore, mMP enumeration in this study was conducted 
at low flow rate, which was 10 µL/min. Sample acquisition at low flow rate also 
maintains the single stream of mMP that passes through the fluidic system and 
prevents doublet detection.  
 
Monocytic MP staining with antibodies directed towards antigens of origin cells is the 




blood (Barteneva et al., 2013). Meanwhile, Annexin-V, a family of calcium-dependent 
phospholipid binding proteins was used as a common marker for mMP detection (Fink 
et al., 2011). Staining of mMP with Annexin-V in combination with other surface 
antibodies allows for targeting of monocyte-derived MP and prevents acquisition of 
false events (Dey-Hazra et al., 2010). In this study, Annexin-V was used in 
combination with anti-CD14 or anti-CD16 to detect mMP derived primarily from 
monocyte subtypes. As monocytes express CD14 and CD16 on their surface (Mandl 
et al., 2014), mMP were identified by the positive expression of PS with CD14 or 
CD16. To the best of our knowledge, this is the first study that characterise the surface 
phenotypes of mMP derived from CD14+ monocytes and CD16+ monocytes. 
 
Based on flow cytometry analysis, CD14 and CD16 were expressed on all 
unstimulated and LPS-stimulated monocyte subtypes, which is similar to previous 
report (Yona and Jung, 2010). However, the expression intensity of these antigens 
differed across cell types. CD14 was highly expressed on unstimulated and LPS-
stimulated whole monocytes and CD14+ monocytes but not on CD16+ monocytes. This 
finding supports the previous report that CD14 is abundantly expressed on whole 
monocytes (Naeim et al., 2018), but low on CD16+ monocytes (Hofer et al., 2015). 
Meanwhile, CD16 expression was low on all unstimulated and LPS-stimulated 
monocyte subtypes, which is possibly due to low frequency of CD16+ monocytes in 
the circulation. Previous studies have reported that CD14+ monocytes account for 90% 
and CD16+ monocytes constitute 10% of total monocytes in healthy individuals 
(Mukherjee et al., 2015; Sánchez-Torres et al., 2001). Taken together, these findings 
suggest that different monocyte subsets display different levels of CD14 and CD16 




LPS stimulation resulted in down regulation of CD14 and CD16 expressions on all 
stimulated cells, with the exception for CD16 on CD16+ monocytes. The type of 
stimulants used may alter the intensity of surface antigen expressions on the cell (van 
der Vlist et al., 2012). In line with previous results, the loss of CD14 (Thaler et al., 
2016) as well as CD16 expression on whole blood (Poehlmann et al., 2009) and 
monocytes (Belge et al., 2002) following LPS stimulation has been observed. During 
inflammation, the loss of CD14 may be correlated with internalisation of CD14 by the 
cells (Buckner et al., 2011) or shedding from the cells in soluble form, known as 
soluble CD14 (sCD14) (Bazil and Strominger, 1991; Buckner et al., 2011). Thus, we 
suggest that reduced CD14 on all stimulated monocyte subtypes may be due to the 
activation effect of LPS on the cells, initiating rearrangement of cytoskeletons for 
mMP budding.  
 
CD16+ monocytes have been previously reported to be elevated up to 40% in 
pathological state (Sánchez-Torres et al., 2001) such as during trauma, sepsis, (Kratofil 
et al., 2017) and cardiovascular diseases (Libby et al., 2013). The increased expression 
of CD16 on CD16+ monocytes by LPS in this study indicates that CD16+ monocytes 
may play a significant role in inflammation as previously reported (Ong et al., 2018). 
The increased CD16 expression may have resulted from the transition process of 
monocytes from classical monocytes to non-classical CD16+ monocytes following 
stimulation (Ziegler-Heitbrock et al., 2010). 
 
On the other hand, a previous study has shown that CD14 expression on MM6 and 
THP-1 cell lines was increased upon LPS treatment (Wen et al., 2014). The different 




used, in which this study used isolated human monocyte subtypes instead of monocytic 
cell lines which were used in other study. This important difference explains that the 
same type of stimuli may give rise to distinct phenotypic expression pattern by 
different cell types (Barteneva et al., 2013).  
 
 
4.2 Expression of CD14 and CD16 on monocyte subsets-derived mMP 
The absolute count of mMP released was further determined using Trucount beads 
(Orozco and Lewis, 2010). Our results have shown that LPS-stimulated monocytes 
resulted in higher mMP count compared to unstimulated monocytes. This result 
indicates that LPS enhanced the release of mMP from stimulated whole monocytes, 
CD14+ monocytes and CD16+ monocytes. Similar to our result, previous study has 
shown that LPS initiates cellular changes in THP-1 and MM6 monocytic cells line, 
thus lead to mMP shedding (Wen et al., 2014). Additionally, LPS stimulation which 
mimics infection suggests that the level of mMP may be increased during disease 
condition as previously reported (Kornek et al., 2012). Elevation of mMP level has 
been observed in various clinical state including acute coronary syndrome (ACS) 
(Suades et al., 2016), diabetes, hypertension (Ogata et al., 2006), and atherosclerosis 
(Paudel et al., 2016). 
 
The expression of CD14 and CD16 on mMP was further assessed on mMP. In this 
study, low levels of mMP derived from unstimulated whole monocytes, CD14+ 
monocytes, and CD16+ monocytes were detected, indicating ongoing vesiculation. A 
previous study has reported that low level of MP has been detected in healthy 




events such as programmed cell death (Meziani et al., 2010) or cell growth (Camussi 
et al., 2010). In an in vitro study, pre-analytical processes including blood sampling, 
centrifugation and cell culture processes may induce the release of some mMP 
(Lacroix et al., 2011). This study has also shown that mMP express CD14 and CD16 
similar to their origin cells. The expression of similar surface marker to origin cells on 
mMP has been widely described (Halim et al., 2016; Nomura et al., 2008). For 
instance, platelet-derived MP express CD41 and CD62P (Yari et al., 2018), while 





















4.3 Monocytic microparticles in coagulation 
Blood coagulation is one of the vital activities during inflammation, which reduces 
bacterial dissemination via bloodstream by the formation of blood clot at the site of 
inflammation (Halim et al., 2016). Tissue factor (TF) or CD142 is a primary activator 
of the extrinsic coagulation cascade (Chiva-Blanch et al., 2017). Tissue factor initiates 
the coagulation pathway by acting as an allosteric cofactor for plasma clotting protease 
factor VIIa (FVIIa), forming the enzymatic complex TF–FVIIa that triggers clotting 
protein factors IX and X (Rao and Pendurthi, 2012). Meanwhile, phosphatidylserine 
(PS) is an anionic phospholipid which recruits the components of the clotting cascade, 
triggered by electrostatic interaction of PS and positively charged γ-carboxyglutamic 
acid (GLA) domains in the clotting proteins (Owens and Mackman, 2011). Both TF 
and PS play a significant role in the coagulation process.  
 
Monocytic MP express TF and PS on their surface, which suggests their function in 
blood clotting activity (Aleman et al., 2011). In this study, TF expression was 
increased on whole monocytes, CD14+ monocytes, and CD16+ monocytes in the 
presence of LPS, which is similar to a previous report (Egorina et al., 2005). As TF 
involves in coagulation, increased TF expression on monocytes may be a part of the 
innate immune response to prevent the spread of pathogenic agents (Bode and 
Mackman, 2014), thus containing the infection locally. In this study, TF expression 
was increased on LPS-stimulated monocyte-derived mMP which was similar to 






Monocytic MP are involved in coagulation and may act as a procoagulant (Aleman et 
al., 2011) or anticoagulant (Mooberry and Key, 2016). As TF was expressed on mMP, 
the coagulation potential of mMP was further assessed using prothrombin (PT) time 
assay. Under normal physiological state, the coagulation process occurs naturally 
between 11 and 15 seconds when assessed using PT assay (Barmore and Burns, 2018).  
 
This study demonstrated that plasma clotting time measurement was unaffected by the 
presence of both unstimulated and stimulated monocytes despite an up regulation of 
TF on stimulated monocytes. It was previously reported that TF may be expressed on 
activated monocytes but does not trigger coagulation cascade, which may be due to 
TF encryption (Bach, 2006). TF encryption is a post-translational suppression of TF 
procoagulant activity (PCA), whereby TF may bind to FVII or FVIIa but unable to 
fully activate FIX or FX and thus fails to trigger coagulation cascade (Rao et al., 2012). 
Tissue factor encryption may be due to sequestering of TF in the lipid raft, which is 
rich in cholesterol (Chen and Hogg, 2013), dimerisation and oligomerisation of TF 
(Bach, 2006) as well as presence of anticoagulant phospholipids (Rao and Pendurthi, 
2012), thus preventing the interaction and activation of TF. However, another study 
has demonstrated that LPS-activated monocytes significantly induced coagulation 
(Øvstebø et al., 2012). This discrepancy may be due to differences between the stimuli 
used. In this study, LPS from E.coli strain O26:B6 was used, which was different from 
other study. In addition, different LPS forms may result in different effects on 
monocytes. Exposure of human monocytes to LPS from wild-type N. meningitidis 
resulted in higher TF activity compared to LPS-deficient N. meningitidis, although 




Monocytic MP derived from LPS-stimulated whole monocytes results in significant 
plasma clotting time compared to their unstimulated counterparts, emphasising their 
potential procoagulant property. This data are similar to previous study, where mMP 
derived from monocytes reduced plasma clotting time, thus acting as a procoagulant 
(Wen et al., 2014). As a higher concentration of mMP may promote faster coagulation 
formation, they possibly contribute in thrombosis progression (Owens and Mackman, 
2011). Tissue factor-bearing MP are highly procoagulant and have been attributed to 
thrombosis in many diseases including sepsis and cancer (Feng et al., 2010). However, 
whether this procoagulant potential is mainly contributed by TF, PS, or the interaction 
between TF and PS remains unknown. Previously, the procoagulant properties of 
mMP were attributed to TF activity, in which mMP derived from monocytes and THP-
1 cells supported thrombin generation and fibrin formation and increased fibrin 
network density in a TF-dependent manner (Aleman et al., 2011). On the other hand, 
another study has reported that mMP derived from monocytes initiate blood 
coagulation in a TF-independent manner and are more reliant on PS on their surface 
(Wen et al., 2014). The increased TF expression on mMP as well as altered 
prothrombin time in this study suggests that the procoagulant properties of mMP are 
mainly TF-dependent and regulated through the extrinsic pathway. Hence, further 








4.4 Monocytic microparticles in endothelial cell activation 
As inflammation and coagulation are closely related, mMP could possibly play an 
important role in inflammation. Monocytic MP have been reported to promote 
inflammatory activities in response to infection (Halim et al., 2016). The interaction 
between MP and endothelial cells during inflammation has been shown in a previous 
in vitro study (Wen et al., 2014). However, information regarding the ability of mMP 
to interact with endothelial cells is limited. In this study, the role of mMP in activating 
endothelial cells was further assessed in a culture condition.   
 
A standard curve is used to determine the dynamic range of an assay, detection limit, 
and quantification limit (Svec et al., 2015). In this study, the standard curve showed 
that real-time PCR assays provided reliable and accurate results as high linearity of 
slope (r2 ≥ 0.98) over five orders of RNA concentrations of 10, 5, 2.5, 1.25 and 0.625 
ng as well as high efficiency for all genes used were obtained (Appendix B). A starting 
RNA concentration of 10 ng was chosen as the optimal RNA concentration as it 
generated the highest output of targeted gene amplification at the lowest cycle 
compared to other RNA concentrations. Dissociation curves of all genes were also 
assessed to ensure the specificity of the primer used. The dissociation curves showed 
that a single peak was plotted for all primers used, which indicates that the primer 
specifically targeted the genes of interest (Appendix D). 
 
We have shown that the number of mMP derived from whole monocytes, CD14+ 
monocytes, and CD16+ monocytes was increased following LPS stimulation, 
indicating the elevation of mMP in inflammatory condition. During inflammation, the 




cells, is pivotal in initiating transendothelial migration of monocytes to the site of 
infection (Wang et al., 2014), thus endothelial cells are potentially the main effector 
cells of mMP (Lovren and Verma, 2013). Monocytic MP are involved in endothelial 
dysfunction, vascular inflammation, and sepsis (Hoyer et al., 2012). To date, the exact 
mechanism carried out by mMP in regulating endothelial activation and function is 
unclear. Therefore, the interaction between mMP derived from monocytes and 
endothelial cells were further assessed by measuring the level of CD31 as well as 
adhesion molecules including ICAM-1 and VCAM-1 expressed by endothelial cells. 
 
Monocytic MP derived from unstimulated and stimulated monocytes increased the 
expression of CD31, ICAM-1, and VCAM-1 on endothelial cells at various intensities. 
Monocytic MP derived from stimulated monocytes up regulated CD31 and adhesion 
molecules higher than those activated by LPS, which suggests that mMP activate 
endothelial cells. Previously, 300 µg/mL of mMP derived from stimulated THP-1 was 
able to activate endothelial cells, resulting in the expression of ICAM-1, VCAM-1, 
and E-selectin after 2 hours culture (Wang et al., 2011). It has been reported that mMP 
mediate the activation of endothelial cells via IL-1β-dependent pathway (Wang et al., 
2011). Monocytic MP regulation involves the activation of intracellular signalling 
pathway by ERK1/2 phosphorylation and degradation of IκB-α, which results in NF-
κB translocation, thus leading to the expression of ICAM-1, VCAM-1 and E-selectin 
by endothelial cells (Wang et al., 2011). Subsequently, the expression of ICAM-1, 
VCAM-1, and E-selectin facilitate monocyte extravasation through the endothelial 
cells of the blood vessels to the sites of inflammation (Halim et al., 2016). Thus, these 




amplification of inflammation by enhancing adhesion molecule expressions and 
facilitating transmigration of monocytes (Lee et al., 2014).  
 
In this study, endothelial cell activation was mainly regulated by mMP since 
endothelial cells were initially cultured in a serum-starved condition prior to culture 
with mMP as previously recommended (Chowdhury et al., 2006). Serum components 
such as growth factors may stimulate and activate cells, thus generating false positive 
results (Antypas et al., 2014). Additionally, as eMP are also able to enhance adhesion 
molecule expressions, culture of mMP with endothelial cells for 2 hours was able to 
up regulate adhesion molecule expression without inducing the vesiculation of 
endothelial cells. A previous study has demonstrated that the level of eMP release 
following TNF-α stimulation for 1 and 2 hours were consistent with the basal level at 
0 hour (Lee et al., 2014). The increased endothelial cell vesiculation was only observed 
at 4 hours of stimulation and eMP was increased over time.  
 
Additionally, as mMP are also released constitutively under physiological condition 
especially during cell growth (Camussi et al., 2010; Ratajczak et al., 2006), their role 
in physiology during healthy state should not be ignored. A previous report has 
suggested that MP derived from various cells under normal haemostasis condition are 
involved in cell signalling and transfer of membrane proteins (Ståhl et al., 2019). For 
example, MP derived from platelets mediate the transfer of adhesion molecules from 
platelets to haematopoietic cell and endothelial cells, thus enhancing their adhesion 
capacity and engraftment (Baj-Krzyworzeka et al., 2002). As CD31, ICAM-1, and 
VCAM-1 expressions by endothelial cells can be enhanced by mMP derived from 




to endothelial cells. Taken together, mMP are beyond than inert cell fragments but are 
capable of altering the response of their effector cells and involve in cell–cell 
interactions as biological active communicators during physiological and pathological 
conditions (Wen et al., 2014). To our knowledge, this is the first study that 
demonstrates the potential role of mMP derived from human monocytes. 
 
In addition to endothelial cell marker expressions, the ability of mMP in inducing 
vesiculation of eMP was also assessed. A previous report has shown that elevation of 
eMP is a hallmark of endothelial cell activation (Wassmer et al., 2006). The finding 
from other study has demonstrated that mMP were able to induce the release of eMP 
in an in vitro brain inflammation model (Wang et al., 2011). Consistent with this study, 
the increased eMP release upon culture with mMP derived from stimulated monocytes 
was observed. A positive correlation between elevated number of eMP and coronary 
endothelial function impairment was observed in patients with coronary artery disease 
(Wang et al., 2014). Additionally, worsening of pulmonary and capillary leak reflected 
by the high number of eMP release was previously demonstrated in vivo (Densmore et 
al., 2006). Therefore, these findings suggest that mMP are able to enhance the 
vesiculation of eMP and they may play important role in exacerbation of vascular 








CHAPTER 5  
CONCLUSION 
 
In conclusion, characterisation and assessment of the potential role of mMP is 
challenging. In this study, cell surface phenotypes of mMP was characterised. This 
study shows that whole monocytes, CD14+ monocytes, and CD16+ monocytes 
expressed both CD14 and CD16 on their surface at different intensities and mMP 
inherit their origin cell identity. Distinct cell types may give rise to mMP with different 
phenotypic profiles. Additionally, Annexin-V in combination with CD14 or CD16 are 
potential cell surface markers for mMP detection. Moreover, the coagulation potential 
of mMP was assessed in this study. Flow cytometry analysis demonstrated that PS and 
TF were expressed on whole monocytes, CD14+ monocytes, and CD16+ monocytes. 
This suggests their attribution in the coagulation process. Likewise, PT analysis 
showed that mMP derived from stimulated monocytes shortened the plasma clotting 
time. Based on our findings, mMP display TF-dependent procoagulant property. In 
addition, the potential role of mMP in endothelial cell activation was further assessed. 
Monocytic MP derived from both unstimulated and stimulated monocytes enhanced 
the expression of CD31, ICAM-1, and VCAM-1 by endothelial cells, as well as 
induced the vesiculation of eMP in a culture condition. These results provide further 
evidence on the important role of mMP as biological messengers in cell signalling 







5.1 Study limitation and future study 
This study has some limitations. Thus, further studies are recommended as follows: 
1. The concentration of monocytes as well as CD14+ monocytes and CD16+ 
monocytes was limited since circulating monocytes population constitutes only 2% 
to 10% of human blood. Therefore, the use of apheresis technique is highly 
recommended for leucocyte isolation in order to increase monocyte concentrations. 
 
2. The morphology and size of mMP derived from monocyte subsets has not been 
identified. Therefore, characterisation of mMP by using scanning electron 
microscope (SEM), and nanoparticle tracking analysis (NTA) is recommended.  
 
3. This study demonstrated that the presence of TF and PS on the surface of mMP 
exhibited procoagulant property. However, the exact role of either TF or PS in 
coagulation by mMP remains unclear. Therefore, further studies to assess thrombin 
generation, fibrin generation and inhibitory test are recommended to identify the 
possible mechanism in mMP-dependent coagulation. 
 
4. This study showed that mMP up regulated the expression of CD31 and adhesion 
molecules by endothelial cell in a culture condition. Previous study has reported the 
potential role of mMP in enhancing cytokines secretion by monocytes which 
resulted in endothelial cell activation. Therefore, it is recommended to assess the 
role of cytokines released by monocytes in the presence of mMP such as IL-1β and 





5. Information regarding cytoplasmic protein, lipids and genetic profile of mMP 
remains unclear. Therefore, it is recommended to determine protein, lipids and 
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Appendix A: RNA integrity test. Gel electrophoresis was conducted for 50 minutes 
at 70 V. Top band shows 28s RNA and lower band shows 18s RNA indicating high 














Appendix B: Efficiency of real-time PCR analysis. Standard curves of each targeted 
genes; A) GAPDH, B) ICAM-1 and C) VCAM-1 are generated using 2-fold dilution. 








A) GAPDH B) ICAM-1
 









Appendix C: Cell viability of PBMC. Peripheral blood mononuclear cells (PBMC) 
were incubated with 100 ng/mL, 1 µg/mL and 5 µg/mL LPS. Following 18 hours 
culture, cell viability was measured by Trypan blue assay. Data are representative of 
three independent experiments. Error bar represent mean ± standard error of the mean 














Appendix D: Dissociation curves of GAPDH, ICAM-1 and VCAM-1. Dissociation 
curves of A) GAPDH, B) ICAM-1 and C) VCAM-1 show a single peak which indicate 
the primer used are specifically targeted on the interest genes. Non-template control 
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Human Research Ethics Committee USM (HREC) 
Universiti Sains Malaysia 
Kampus Kesihatan, 
16150 Kubang Kerian. Kelantan. Malaysia 
T : (6):)9-767 31XXJ/2354/2362 
F : (6):)9-767 2351 
E : jepem@usm my 
l : www.jepem.kk.usm.my 
v.tWvV.usm.my 
Study Protocol Title: The Role of Monocytic Microparticles (mMP) in Endothelial Cell Function. 
Dear Dr: 
We wish to inform you t hat the Jawatankuasa Etika Penyelidikan Man usia, Universiti Sa ins Malaysia 
(JEPeM-USM) acknowledged receipt of Continuing Review Application dated 4'' January 2018. 
Upon review of JEPeM-USM Form 3(B) 2017: Continuing Review Application Form, the committee's 
decision for the EXTENSION OF APPROVAL IS APPROVED (start from 1" February 2018 till 3151 
January 2019). The report is noted and has been included in the protocol file. 
JEPeM USM has noted that there is no research activity took place during the period of 1" November 
2017 until31" January 2018. The report is noted and has been included in the protocol f ile. 
Principle Investigator (PI) should aware and concern about the ethical expiration of the study in 
the future. 
Thank you for your continuing compliance with the requirements of the JEPeM-USM. 
"ENSURING A SUSTAINABLE TOMORROW" 
. DR. AZLAN HUSIN) 
Deputy Chai erson 
Jawatankuasa Etika Penyelidikan (Manusia), JEPeM 
Universiti Sa ins Malaysia 
c.c Secretary 
Jawatankuasa Etika Penyelidikan (Manusia), JEPeM 




Regulatory Agency (NPRA) 
Forum for Ethical Review Committees 








Appendix G: Abstract for poster presentation. The title of presentation was 
assessment of cell surface phenotypes and coagulation properties of monocytic 
microparticles (mMP) derived from peripheral blood mononuclear cells (PBMC). The 
International Conference on Infection and Immunity 2017 was held on 5th and 6th April 










Appendix H: Certificate of award. The International Conference on Infection and 
Immunity 2017 was held on 5th and 6th April 2017 at Renaissance Hotel, Kota Bharu, 
Kelantan. 
PUSAT PENGAJIAN SAINS KESIHATAN 
SCHOOL OF HEALTH SCIENCES ~~."""'"'.~  ...... .... ,. 
150300\ :ZOOI! Cirdiecl 
CERTIFICATE OF AWARD 
SECOND PRIZE WINNER 




INTERNATIONAL CONFERENCE ON 
INFECTION AND IMMUNITY 20 17 . 
Challenqinq diseases with a united front 
ON 
APRIL 5-6. 2017 
RENAISSANCE HOTEL, KOTA BHARU, 
KELANTAN, MALAYSIA 
DR. NURHIDANATASHA ABU BAKAR PROFESOR DR. NORAZMI MOHO NOR 
CHAIRMAN 
INTERNATIONAL CONFERENCE ON 
INFECTION AND IMMUNITY 2017 
DEAN 
SCHOOL OF HEALTH SCIENCES 
UNIVERSITI SAINS MALAYSIA 
